

 



<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
  "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"
      xmlns:foaf="http://xmlns.com/foaf/0.1/"
      xmlns:dc="http://purl.org/dc/terms/"
      xmlns:doi="http://dx.doi.org/"
      xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
      xmlns:xsd="http://www.w3.org/2001/XMLSchema-datatypes#"
      lang="en" xml:lang="en"
      itemscope itemtype="http://schema.org/Article"
      class="no-js">
<head prefix="og: http://ogp.me/ns#">
  <title>PLOS ONE: The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction</title>


<link rel="stylesheet" type="text/css"  href="/css/global-min.css?v=izteQ6tu7kgsJZW_xmrYizvKiHM" />


    <!--[if lte IE 7]>
<link rel="stylesheet" type="text/css"  href="/css/lte_ie7-min.css?v=3bykQUyQmReeuobVyPozcJ9LxRc" />
    <![endif]-->


<link rel="stylesheet" type="text/css"  href="/css/jquery-ui-min.css?v=eXDHTEJM0lIAmDe5k0I0Ad4nxNo" />


<link rel="stylesheet" type="text/css"  href="/css/journal.css?v=T7ZVxJfgk9jNxLAJ2qHz1vZpgYU" />


<link rel="stylesheet" type="text/css" media="print" href="/css/print-min.css?v=T5lb0B3q6EXBsuDluc5V5w+AkRc" />


  <link rel="stylesheet" href="http://f.fontdeck.com/s/css/js/www.plosone.org/24557.css" type="text/css"/>

  <!--chartbeat -->
  <script type="text/javascript">var _sf_startpt = (new Date()).getTime()</script>
  <script>document.documentElement.className += ' js';</script>

  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <meta http-equiv="X-UA-Compatible" content="IE=EmulateIE7; IE=EmulateIE9"/>
  <meta name="description" content="PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world."/>
  <meta name="keywords" content="PLOS, Public Library of Science, Open Access, Open-Access, Science, Medicine, Biology, Research, Peer-review, Inclusive, Interdisciplinary, Ante-disciplinary, Physics, Chemistry, Engineering"/>
  <meta name="almHost" content="http://alm.plos.org/api/v3/articles"/>
  <meta name="searchHost" content="http://api.plos.org/search" />
  <meta name="termsHost" content="http://api.plos.org/terms" />
  <meta name="solrApiKey" content="plos"/>
  <meta name="almAPIKey" content="3pezRBRXdyzYW6ztfwft" />
  <meta name="currentJournal" content="PLoSONE" />
  <meta name="almRequestBatchSize" content="" />

  <meta name="citation_publisher" content="Public Library of Science"/>
  <meta name="citation_doi" content="10.1371/journal.pone.0000840"/>
  <meta name="dc.identifier" content="10.1371/journal.pone.0000840" />

    <meta name="citation_title" content="The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction"/>
    <meta itemprop="name" content="The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction"/>

      <meta name="citation_author" content="John S. Brownstein"/>
            <meta name="citation_author_institution" content="Children's Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, United States of America"/>
            <meta name="citation_author_institution" content="Division of Emergency Medicine, Children's Hospital Boston, Boston, Massachusetts, United States of America"/>
            <meta name="citation_author_institution" content="Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America"/>
      <meta name="citation_author" content="Margarita Sordo"/>
            <meta name="citation_author_institution" content="Children's Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, United States of America"/>
            <meta name="citation_author_institution" content="Decision Systems Group, Brigham and Women's Hospital, Boston, Massachusetts, United States of America"/>
      <meta name="citation_author" content="Isaac S. Kohane"/>
            <meta name="citation_author_institution" content="Children's Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, United States of America"/>
            <meta name="citation_author_institution" content="Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America"/>
            <meta name="citation_author_institution" content="Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, United States of America"/>
            <meta name="citation_author_institution" content="Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America"/>
      <meta name="citation_author" content="Kenneth D. Mandl"/>
            <meta name="citation_author_institution" content="Children's Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, United States of America"/>
            <meta name="citation_author_institution" content="Division of Emergency Medicine, Children's Hospital Boston, Boston, Massachusetts, United States of America"/>
            <meta name="citation_author_institution" content="Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America"/>
            <meta name="citation_author_institution" content="Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, United States of America"/>

    <meta name="citation_date" content="2007/9/5"/>

  <meta name="citation_pdf_url" content="http://dx.plos.org/10.1371/journal.pone.0000840.pdf" />

      <meta name="citation_journal_title" content="PLOS ONE" />
    <meta name="citation_firstpage" content="e840"/>
    <meta name="citation_issue" content="9"/>
    <meta name="citation_volume" content="2"/>
    <meta name="citation_issn" content="1932-6203"/>

    <meta name="citation_journal_abbrev" content="PLoS ONE" />

      <meta name="citation_reference" content="citation_title=Mortality from coronary heart disease and acute myocardial infarction–United States, 1998.; citation_journal_title=MMWR Morb Mortal Wkly Rep; citation_volume=50; citation_number=1; citation_pages=90-93; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=Heart Disease and Stroke Statistics-2005 Update.; citation_number=2; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Physical exertion as a trigger of acute myocardial infarction. Triggers and Mechanisms of Myocardial Infarction Study Group.; citation_author=SN Willich; citation_author=M Lewis; citation_author=H Lowel; citation_author=HR Arntz; citation_author=F Schubert; citation_journal_title=N Engl J Med; citation_volume=329; citation_number=3; citation_pages=1684-1690; citation_date=1993; " />
      <meta name="citation_reference" content="citation_title=Decline in the risk of myocardial infarction among women who stop smoking.; citation_author=L Rosenberg; citation_author=JR Palmer; citation_author=S Shapiro; citation_journal_title=N Engl J Med; citation_volume=322; citation_number=4; citation_pages=213-217; citation_date=1990; " />
      <meta name="citation_reference" content="citation_title=Dietary fat intake and the risk of coronary heart disease in women.; citation_author=FB Hu; citation_author=MJ Stampfer; citation_author=JE Manson; citation_author=E Rimm; citation_author=GA Colditz; citation_journal_title=N Engl J Med; citation_volume=337; citation_number=5; citation_pages=1491-1499; citation_date=1997; " />
      <meta name="citation_reference" content="citation_title=Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.; citation_author=JS Borer; citation_author=H Pouleur; citation_author=E Abadie; citation_author=F Follath; citation_author=J Wittes; citation_journal_title=Eur Heart J; citation_number=6; citation_date=2007; " />
      <meta name="citation_reference" content="citation_title=A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.; citation_author=H Jick; citation_author=C Vasilakis; citation_author=LA Weinrauch; citation_author=CR Meier; citation_author=SS Jick; citation_journal_title=N Engl J Med; citation_volume=339; citation_number=7; citation_pages=719-724; citation_date=1998; " />
      <meta name="citation_reference" content="citation_title=Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.; citation_author=DK Wysowski; citation_author=A Corken; citation_author=H Gallo-Torres; citation_author=L Talarico; citation_author=EM Rodriguez; citation_journal_title=Am J Gastroenterol; citation_volume=96; citation_number=8; citation_pages=1698-1703; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.; citation_author=PM Kearney; citation_author=C Baigent; citation_author=J Godwin; citation_author=H Halls; citation_author=JR Emberson; citation_journal_title=Bmj; citation_volume=332; citation_number=9; citation_pages=1302-1308; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.; citation_author=DJ Graham; citation_author=D Campen; citation_author=R Hui; citation_author=M Spence; citation_author=C Cheetham; citation_journal_title=Lancet; citation_volume=365; citation_number=10; citation_pages=475-481; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.; citation_author=J Hippisley-Cox; citation_author=C Coupland; citation_journal_title=Bmj; citation_volume=330; citation_number=11; citation_pages=1366; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.; citation_author=DH Solomon; citation_author=S Schneeweiss; citation_author=RJ Glynn; citation_author=Y Kiyota; citation_author=R Levin; citation_journal_title=Circulation; citation_volume=109; citation_number=12; citation_pages=2068-2073; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.; citation_author=B Caldwell; citation_author=S Aldington; citation_author=M Weatherall; citation_author=P Shirtcliffe; citation_author=R Beasley; citation_journal_title=J R Soc Med; citation_volume=99; citation_number=13; citation_pages=132-140; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.; citation_author=SD Solomon; citation_author=JJ McMurray; citation_author=MA Pfeffer; citation_author=J Wittes; citation_author=R Fowler; citation_journal_title=N Engl J Med; citation_volume=352; citation_number=14; citation_pages=1071-1080; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.; citation_author=NA Nussmeier; citation_author=AA Whelton; citation_author=MT Brown; citation_author=RM Langford; citation_author=A Hoeft; citation_journal_title=N Engl J Med; citation_volume=352; citation_number=15; citation_pages=1081-1091; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Risk of cardiovascular events associated with selective COX-2 inhibitors.; citation_author=D Mukherjee; citation_author=SE Nissen; citation_author=EJ Topol; citation_journal_title=Jama; citation_volume=286; citation_number=16; citation_pages=954-959; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.; citation_author=RS Bresalier; citation_author=RS Sandler; citation_author=H Quan; citation_author=JA Bolognese; citation_author=B Oxenius; citation_journal_title=N Engl J Med; citation_volume=352; citation_number=17; citation_pages=1092-1102; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles.; citation_author=NS Rawson; citation_author=E Malcolm; citation_journal_title=Stat Med; citation_volume=14; citation_number=18; citation_pages=2627-2643; citation_date=1995; " />
      <meta name="citation_reference" content="citation_title=Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records.; citation_author=Y Kiyota; citation_author=S Schneeweiss; citation_author=RJ Glynn; citation_author=CC Cannuscio; citation_author=J Avorn; citation_journal_title=Am Heart J; citation_volume=148; citation_number=19; citation_pages=99-104; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Using laboratory-based surveillance data for prevention: an algorithm for detecting Salmonella outbreaks.; citation_author=LC Hutwagner; citation_author=EK Maloney; citation_author=NH Bean; citation_author=L Slutsker; citation_author=SM Martin; citation_journal_title=Emerg Infect Dis; citation_volume=3; citation_number=20; citation_pages=395-400; citation_date=1997; " />
      <meta name="citation_reference" content="citation_title=Active surveillance of vaccine safety: a system to detect early signs of adverse events.; citation_author=RL Davis; citation_author=M Kolczak; citation_author=E Lewis; citation_author=J Nordin; citation_author=M Goodman; citation_journal_title=Epidemiology; citation_volume=16; citation_number=21; citation_pages=336-341; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Quantitative methods in pharmacovigilance: focus on signal detection.; citation_author=M Hauben; citation_author=X Zhou; citation_journal_title=Drug Saf; citation_volume=26; citation_number=22; citation_pages=159-186; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=Quality control: an application of the cusum.; citation_author=SM Williams; citation_author=BR Parry; citation_author=MM Schlup; citation_journal_title=Bmj; citation_volume=304; citation_number=23; citation_pages=1359-1361; citation_date=1992; " />
      <meta name="citation_reference" content="citation_title=Generalized Linear Models.; citation_author=P McCullagh; citation_author=JA Nelder; citation_number=24; citation_date=1989; citation_publisher=Chapman and Hall; " />
      <meta name="citation_reference" content="citation_title=Commonly Requested Therapeutic Class and Product Information.; citation_number=25; citation_date=2006; citation_publisher=IMS Health; " />
      <meta name="citation_reference" content="citation_title=Secular trends in deaths from cardiovascular diseases: a 25-year community study.; citation_author=Y Gerber; citation_author=SJ Jacobsen; citation_author=RL Frye; citation_author=SA Weston; citation_author=JM Killian; citation_journal_title=Circulation; citation_volume=113; citation_number=26; citation_pages=2285-2292; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.; citation_author=LE Levesque; citation_author=JM Brophy; citation_author=B Zhang; citation_journal_title=Ann Intern Med; citation_volume=142; citation_number=27; citation_pages=481-489; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Implementing syndromic surveillance: a practical guide informed by the early experience.; citation_author=KD Mandl; citation_author=JM Overhage; citation_author=MM Wagner; citation_author=WB Lober; citation_author=P Sebastiani; citation_journal_title= J Am Med Inform Assoc; citation_volume=11; citation_number=28; citation_pages=141-150 [PrePrint published Nov 121, 2003; as doi:2010.1197/jamia.M1356]; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Using temporal context to improve biosurveillance.; citation_author=BY Reis; citation_author=M Pagano; citation_author=KD Mandl; citation_journal_title=Proc Natl Acad Sci U S A; citation_volume=100; citation_number=29; citation_pages=1961-1965; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=Technical description of RODS: a real-time public health surveillance system.; citation_author=FC Tsui; citation_author=JU Espino; citation_author=VM Dato; citation_author=PH Gesteland; citation_author=J Hutman; citation_journal_title=J Am Med Inform Assoc; citation_volume=10; citation_number=30; citation_pages=399-408; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.; citation_author=C Bombardier; citation_author=L Laine; citation_author=A Reicin; citation_author=D Shapiro; citation_author=R Burgos-Vargas; citation_journal_title=N Engl J Med; citation_volume=343; citation_number=31; citation_pages=1520-1528, 1522 p following 1528; citation_date=2000; " />
      <meta name="citation_reference" content="citation_title=Expression of concern: Bombardier et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” N Engl J Med 2000;343:1520-8.; citation_author=GD Curfman; citation_author=S Morrissey; citation_author=JM Drazen; citation_journal_title=N Engl J Med; citation_volume=353; citation_number=32; citation_pages=2813-2814; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Modeling of the temporal patterns of fluoxetine prescriptions and suicide rates in the United States.; citation_author=MS Milane; citation_author=MA Suchard; citation_author=ML Wong; citation_author=J Licinio; citation_journal_title=PLoS Med; citation_volume=3; citation_number=33; citation_pages=e190; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Suicide rates and antidepressant prescribing: a casual or causal relationship?; citation_author=B Baune; citation_author=P Hay; citation_journal_title=PLoS Med; citation_volume=3; citation_number=34; citation_pages=e220; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=COX-2 inhibitors–lessons in drug safety.; citation_author=BM Psaty; citation_author=CD Furberg; citation_journal_title=N Engl J Med; citation_volume=352; citation_number=35; citation_pages=1133-1135; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Failing the public health–rofecoxib, Merck, and the FDA.; citation_author=EJ Topol; citation_journal_title=N Engl J Med; citation_volume=351; citation_number=36; citation_pages=1707-1709; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=The lessons of Vioxx–drug safety and sales.; citation_author=HA Waxman; citation_journal_title=N Engl J Med; citation_volume=352; citation_number=37; citation_pages=2576-2578; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.; citation_author=SE Nissen; citation_author=K Wolski; citation_journal_title=N Engl J Med; citation_volume=356; citation_number=38; citation_pages=2457-2471; citation_date=2007; " />
      <meta name="citation_reference" content="citation_title=Rosiglitazone and cardiovascular risk.; citation_author=BM Psaty; citation_author=CD Furberg; citation_journal_title=N Engl J Med; citation_volume=356; citation_number=39; citation_pages=2522-2524; citation_date=2007; " />
      <meta name="citation_reference" content="citation_title=Evaluating drug effects in the post-Vioxx world: there must be a better way.; citation_author=J Avorn; citation_journal_title=Circulation; citation_volume=113; citation_number=40; citation_pages=2173-2176; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=COX-2 inhibitors–a lesson in unexpected problems.; citation_author=JM Drazen; citation_journal_title=N Engl J Med; citation_volume=352; citation_number=41; citation_pages=1131-1132; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=The Future of Drug Safety: Promoting and Protecting the Health of the Public.; citation_number=42; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Reform of drug regulation–beyond an independent drug-safety board.; citation_author=WA Ray; citation_author=CM Stein; citation_journal_title=N Engl J Med; citation_volume=354; citation_number=43; citation_pages=194-201; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Remarks of the Acting FDA Commissioner: FDLI's 48th annual conference.; citation_author=LM Crawford; citation_journal_title=Food Drug Law J; citation_volume=60; citation_number=44; citation_pages=99-102; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=MedWatch Reporting by Consumers.; citation_number=45; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=Prescription-event monitoring and reporting of adverse drug reactions.; citation_author=E Heeley; citation_author=J Riley; citation_author=D Layton; citation_author=LV Wilton; citation_author=SA Shakir; citation_journal_title=Lancet; citation_volume=358; citation_number=46; citation_pages=1872-1873; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=Assessments of disproportionality.; citation_author=RD Mann; citation_journal_title=Pharmacoepidemiol Drug Saf; citation_volume=13; citation_number=47; citation_pages=501-502; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole.; citation_author=N Moore; citation_author=G Hall; citation_author=M Sturkenboom; citation_author=R Mann; citation_author=R Lagnaoui; citation_journal_title=Pharmacoepidemiol Drug Saf; citation_volume=12; citation_number=48; citation_pages=271-281; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.; citation_author=BL Strom; citation_journal_title=Jama; citation_volume=292; citation_number=49; citation_pages=2643-2646; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.; citation_author=BM Psaty; citation_author=CD Furberg; citation_author=WA Ray; citation_author=NS Weiss; citation_journal_title=Jama; citation_volume=292; citation_number=50; citation_pages=2622-2631; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)–United States, 1991-2001.; citation_author=W Zhou; citation_author=V Pool; citation_author=F DeStefano; citation_author=JK Iskander; citation_author=P Haber; citation_journal_title=Pharmacoepidemiol Drug Saf; citation_volume=13; citation_number=51; citation_pages=505-510; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Long-term proton pump inhibitor therapy and risk of hip fracture.; citation_author=YX Yang; citation_author=JD Lewis; citation_author=S Epstein; citation_author=DC Metz; citation_journal_title=Jama; citation_volume=296; citation_number=52; citation_pages=2947-2953; citation_date=2006; " />

  <link rel="canonical" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0000840" />

    <meta name="twitter:card" content="summary"/>
    <meta name="twitter:site" content="@plosone"/>
    <meta name="twitter:title" content="The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction"/>
    <meta name="twitter:description" content="BackgroundCOX-2 selective inhibitors are associated with myocardial infarction (MI). We sought to determine whether population health monitoring would have revealed the effect of COX-2 inhibitors on population-level patterns of MI.Methodology/Principal FindingsWe conducted a retrospective study of inpatients at two Boston hospitals, from January 1997 to March 2006. There was a population-level rise in the rate of MI that reached 52.0 MI-related hospitalizations per 100,000 (a two standard deviation exceedence) in January of 2000, eight months after the introduction of rofecoxib and one year after celecoxib. The exceedence vanished within one month of the withdrawal of rofecoxib. Trends in inpatient stay due to MI were tightly coupled to the rise and fall of prescriptions of COX-2 inhibitors, with an 18.5% increase in inpatient stays for MI when both rofecoxib and celecoxib were on the market (P&lt;0.001). For every million prescriptions of rofecoxib and celecoxib, there was a 0.5% increase in MI (95%CI 0.1 to 0.9) explaining 50.3% of the deviance in yearly variation of MI-related hospitalizations. There was a negative association between mean age at MI and volume of prescriptions for celecoxib and rofecoxib (Spearman correlation, &minus;0.67, P&lt;0.05).Conclusions/SignificanceThe strong relationship between prescribing and outcome time series supports a population-level impact of COX-2 inhibitors on MI incidence. Further, mean age at MI appears to have been lowered by use of these medications. Use of a population monitoring approach as an adjunct to pharmacovigilence methods might have helped confirm the suspected association, providing earlier support for the market withdrawal of rofecoxib."/>
      <meta name="twitter:image" content="http://dx.plos.org/10.1371/journal.pone.0000840.g003"/>

  <meta property="og:title" content="The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction" />
  <meta property="og:type" content="article" />
  <meta property="og:url" content="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0000840" />

 <!--end articleInfoX-->

  <link rel="pingback" href="http://www.plosone.org/pingback" />


  <link rel="shortcut icon" href="/images/favicon.ico" type="image/x-icon"/>
  <link rel="home" title="home" href="/"/>
  <link rel="alternate" type="application/rss+xml"
        title="PLOS ONE: New Articles"
        href="http://www.plosone.org/article/feed"/>
</head>
<body>

  <div id="page-wrap">
    <div id="topbanner" class="cf">

<!-- Div for the ad at the top of journal home page-->
<div class="center">
  <div class="title">Advertisement</div>
  <iframe id='a3ac9da4' name='a3ac9da4'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=345&amp;cb=3222'
    frameborder='0' scrolling='no' width='730' height='90'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a3ac9da4&amp;cb=8106'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=345&amp;cb=6032&amp;n=a3ac9da4'
      border='0' alt=''/>
    </a>
  </iframe>
</div>    </div>

    <div id="pagehdr-wrap">
      <div id="pagehdr">
        <div id="user" class="nav">
          <ul>
            <li><a href="http://www.plos.org">plos.org</a></li>
            <li><a href="https://register.plos.org/ambra-registration/register.action">create account</a></li>
            <li class="btn-style"><a
              href="/user/secure/secureRedirect.action?goTo=%2Farticle%2FfetchArticle.action%3FarticleURI%3Dinfo%253Adoi%252F10.1371%252Fjournal.pone.0000840">sign in</a>
            </li>
          </ul>
        </div>
        <div class="logo">
          <a href="/"><img src="/images/logo.png" alt="PLOS ONE"></a>
        </div>

<div id="nav-main" class="nav">
  <ul>
        <li id="mn-01"><a href="/taxonomy" class="areas-link">Subject Areas</a></li>
    <li id="mn-02"><a href="javascript:void(0);">For Authors</a>
      <div class="submenu" style="width: 540px; margin-left: -300px;">
        <div class="block">
          <div class="submit-script">
            <h3>Submit your Manuscript</h3>
            <ul>
              <li>Fair, rigorous peer review</li>
              <li>Broad scope and wide reach</li>
            </ul>
            <a href="/static/submissionInstructions" class="btn">get started</a>
          </div>
        </div>
        <div class="menu">
          <ul>
            <li><a href="/static/publish">Why Publish with PLOS ONE</a></li>
            <li><a href="/static/publication">Publication Criteria</a></li>
            <li><a href="/static/editorial">Editorial Policies</a></li>
            <li><a href="/static/guidelines">Preparing A Manuscript</a></li>
            <li><a href="/static/figureGuidelines">Figure and Table Guidelines</a></li>
          <li><a href="/static/supportingInformation">Supporting Information Guidelines</a></li>
            <li><a href="/static/submissionInstructions">Submitting a Manuscript</a></li>
          </ul>
        </div>
      </div>
    </li>

    <li id="mn-03"><a href="javascript:void(0);">About Us</a>
      <div class="submenu" style="width:248px; margin-left:-30px;">
        <div class="menu">
          <ul>
            <li><a href="/static/information">Journal Information</a></li>
            <li><a href="/static/edboard">Editorial Board</a></li>
            <li><a href="/static/reviewerGuidelines">Reviewer Guidelines</a></li>
            <li><a href="/static/almInfo">Article-Level Metrics</a></li>
            <li><a href="/static/license">Open-Access License</a></li>
            <li><a href="/static/downloads">Media Downloads</a></li>
            <li><a href="/static/commentGuidelines">Guidelines for Comments</a></li>
            <li><a href="/static/corrections">Corrections</a></li>
            <li><a href="/static/help">Help Using this Site</a></li>
            <li><a href="/static/contact">Contact Us</a></li>
          </ul>
        </div>
      </div>
    </li>
  </ul>
<div id="db">
  <form name="searchForm" action="/search/simple?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000840" method="get" >
<input type="hidden" name="from" value="globalSimpleSearch" id="from"/><input type="hidden" name="filterJournals" value="PLoSONE" id="filterJournals"/>    <fieldset>
      <legend>Search</legend>
      <label for="search">Search</label>
      <div class="wrap">
        <input id="search" type="text" name="query" placeholder="Search">
        <input type="image" alt="SEARCH" src="/images/icon.search.gif">
      </div>
    </fieldset>
  </form>
    <a id="advSearch" href="/search/advanced?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000840&filterJournals=PLoSONE">advanced search</a>
</div></div>

      </div>
      <!-- pagehdr-->
    </div>
    <!-- pagehdr-wrap -->

  <!--body and html tags gets closed in global_footer.ftl-->
<script type="text/javascript" src="/javascript/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>

<div id="pagebdy-wrap">
  <div id="pagebdy">

    <div id="article-block" class="cf">

<div class="article-meta cf">
  <ul id="almSignPost" style="display: none;"></ul>
  <div class="article-type">
    <span class="type oa">Open Access</span>
      <span class="type pr">Peer-Reviewed</span>
  </div>
</div>

<div class="header" id="hdr-article">

<div class="article-kicker">
      <span id="article-type-heading">
        Research Article
      </span>
</div>  <h1 property="dc:title" datatype="" rel="dc:type" href="http://purl.org/dc/dcmitype/Text">
    The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction
  </h1>

  <ul class="authors">
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            John S. Brownstein
              <span class="corresponding">mail</span>, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              <p><span class="email">*</span>To whom correspondence should be addressed. E-mail: <a href="mailto:john_brownstein@harvard.edu">john_brownstein@harvard.edu</a></p>

                <p>Affiliations:
                  Children's Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, United States of America, 
                  Division of Emergency Medicine, Children's Hospital Boston, Boston, Massachusetts, United States of America, 
                  Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Margarita Sordo, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliations:
                  Children's Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, United States of America, 
                  Decision Systems Group, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Isaac S. Kohane, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliations:
                  Children's Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, United States of America, 
                  Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America, 
                  Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, United States of America, 
                  Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Kenneth D. Mandl
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliations:
                  Children's Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, United States of America, 
                  Division of Emergency Medicine, Children's Hospital Boston, Boston, Massachusetts, United States of America, 
                  Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America, 
                  Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
  </ul>
  <ul class="date-doi-line">
    <li>Published: September 05, 2007</li>
    <li>DOI: 10.1371/journal.pone.0000840</li>
  </ul>


</div><!--end header-->
<div class="main cf" id="pjax-container">
  

<div class="nav items-5" id="nav-article">
  <ul>
  <li>
        <span class="active" name="article">Article</span>
  </li>
  <li>
      <a href="/article/authors/info%3Adoi%2F10.1371%2Fjournal.pone.0000840" name="authors">About the Authors</a>
  </li>
  <li>
      <a href="/article/metrics/info%3Adoi%2F10.1371%2Fjournal.pone.0000840" name="metrics">Metrics</a>
  </li>
  <li>
      <a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0000840" name="comments">Comments</a>
  </li>
  <li>
      <a href="/article/related/info%3Adoi%2F10.1371%2Fjournal.pone.0000840" name="related">Related Content</a>
  </li>
  </ul>
</div>

<script type="text/javascript">
  var selected_tab = "article";
</script>
  <div id="figure-thmbs" class="carousel cf">
    <div class="wrapper">
      <div class="slider">
              <div class="item">
                <a href="#pone-0000840-g001" data-doi="info:doi/10.1371/journal.pone.0000840" data-uri="info:doi/10.1371/journal.pone.0000840.g001" title="Figure 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000840.g001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000840-g002" data-doi="info:doi/10.1371/journal.pone.0000840" data-uri="info:doi/10.1371/journal.pone.0000840.g002" title="Figure 2">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000840.g002&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000840-t001" data-doi="info:doi/10.1371/journal.pone.0000840" data-uri="info:doi/10.1371/journal.pone.0000840.t001" title="Table 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000840.t001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000840-g003" data-doi="info:doi/10.1371/journal.pone.0000840" data-uri="info:doi/10.1371/journal.pone.0000840.g003" title="Figure 3">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000840.g003&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
      </div>
    </div>
  </div>

  <div class="nav-col">
    <div class="nav" id="nav-article-page">
      <ul>
        <li class="nav-col-comments"><a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0000840">Reader Comments (0)</a></li>
          <li id="nav-figures"><a data-doi="info:doi/10.1371/journal.pone.0000840" >Figures</a></li>
      </ul>
    </div>
  </div>

  <div class="article">







<div class="abstract"><a id="abstract0" name="abstract0" toc="abstract0" title="Abstract"></a><h2>Abstract</h2>
<h3>Background</h3>
<a id="article1.front1.article-meta1.abstract1.sec1.p1" name="article1.front1.article-meta1.abstract1.sec1.p1"></a><p>COX-2 selective inhibitors are associated with myocardial infarction (MI). We sought to determine whether population health monitoring would have revealed the effect of COX-2 inhibitors on population-level patterns of MI.</p>


<h3>Methodology/Principal Findings</h3>
<a id="article1.front1.article-meta1.abstract1.sec2.p1" name="article1.front1.article-meta1.abstract1.sec2.p1"></a><p>We conducted a retrospective study of inpatients at two Boston hospitals, from January 1997 to March 2006. There was a population-level rise in the rate of MI that reached 52.0 MI-related hospitalizations per 100,000 (a two standard deviation exceedence) in January of 2000, eight months after the introduction of rofecoxib and one year after celecoxib. The exceedence vanished within one month of the withdrawal of rofecoxib. Trends in inpatient stay due to MI were tightly coupled to the rise and fall of prescriptions of COX-2 inhibitors, with an 18.5% increase in inpatient stays for MI when both rofecoxib and celecoxib were on the market (P&lt;0.001). For every million prescriptions of rofecoxib and celecoxib, there was a 0.5% increase in MI (95%CI 0.1 to 0.9) explaining 50.3% of the deviance in yearly variation of MI-related hospitalizations. There was a negative association between mean age at MI and volume of prescriptions for celecoxib and rofecoxib (Spearman correlation, −0.67, P&lt;0.05).</p>


<h3>Conclusions/Significance</h3>
<a id="article1.front1.article-meta1.abstract1.sec3.p1" name="article1.front1.article-meta1.abstract1.sec3.p1"></a><p>The strong relationship between prescribing and outcome time series supports a population-level impact of COX-2 inhibitors on MI incidence. Further, mean age at MI appears to have been lowered by use of these medications. Use of a population monitoring approach as an adjunct to pharmacovigilence methods might have helped confirm the suspected association, providing earlier support for the market withdrawal of rofecoxib.</p>

</div>


<div class="articleinfo"><p><strong>Citation: </strong>Brownstein JS, Sordo M, Kohane IS, Mandl KD (2007) The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction. PLoS ONE 2(9):
          e840.
            doi:10.1371/journal.pone.0000840</p><p><strong>Academic Editor: </strong>Joel Lexchin, York University, Canada</p><p><strong>Received:</strong> June 27, 2007; <strong>Accepted:</strong> August 8, 2007; <strong>Published:</strong> September 5, 2007</p><p><strong>Copyright:</strong> © 2007 Brownstein et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p><p><strong>Funding: </strong>This work was supported grant numbers R01 LM007677-01 and 5U54LM008748-02.20 from the National Library of Medicine, National Institutes of Health, grant number 200510MFE-154492 from the Canadian Institutes of Health Research and a grant from the Massachusetts Institute of Technology Center for Biomedical Innovation. The funders had no role in the design or conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.</p><p><strong>Competing interests:</strong> The authors have declared that no competing interests exist.</p></div>





<div id="section1" class="section"><a id="s1" name="s1" toc="s1" title="Introduction"></a><h3>Introduction</h3><a id="article1.body1.sec1.p1" name="article1.body1.sec1.p1"></a><p>In the United States, almost a million people are hospitalized, and 200,000-300,000 die each year of myocardial infarction (MI).<a href="#pone.0000840-1">[1]</a>, <a href="#pone.0000840-American1">[2]</a> Rates of MI have increased over the last century and are attributable to lifestyle risk factors, including smoking, obesity, exercise and diet.<a href="#pone.0000840-Willich1">[3]</a>, <a href="#pone.0000840-Rosenberg1">[4]</a>, <a href="#pone.0000840-Hu1">[5]</a> While non-cardiovascular target drugs such as fenfluramine, dexfenfluramine, terfanadine and cisapride have been shown to be risk factors for cardiovascular events <a href="#pone.0000840-Borer1">[6]</a>, <a href="#pone.0000840-Jick1">[7]</a>, <a href="#pone.0000840-Wysowski1">[8]</a>, their effects are rare and are not considered as contributors to long term trends in morbidity and mortality.</p>
<a id="article1.body1.sec1.p2" name="article1.body1.sec1.p2"></a><p>Nonsteroidal anti-inflammatory drugs (NSAIDs) are increasingly implicated in cardiovascular morbidity <a href="#pone.0000840-Kearney1">[9]</a> and Cyclooxygenase-2 (COX-2) selective inhibitors, a class of NSAIDs, have been, in particular, associated with increased risk of MI.<a href="#pone.0000840-Kearney1">[9]</a>, <a href="#pone.0000840-Graham1">[10]</a>, <a href="#pone.0000840-HippisleyCox1">[11]</a>, <a href="#pone.0000840-Solomon1">[12]</a>, <a href="#pone.0000840-Caldwell1">[13]</a>, <a href="#pone.0000840-Solomon2">[14]</a>, <a href="#pone.0000840-Nussmeier1">[15]</a>, <a href="#pone.0000840-Mukherjee1">[16]</a> Rofecoxib was withdrawn from the market after a randomized placebo-controlled trial revealed increased cardiovascular risk in patients with colorectal polyps.<a href="#pone.0000840-Bresalier1">[17]</a> Though similarly associated with cardiovascular risk <a href="#pone.0000840-Kearney1">[9]</a>, celecoxib is still prescribed widely. Many studies have supported an increased individual risk of MI, but the population-level impact of COX-2 selective inhibitor prescription has not been described or quantified despite their substantial market penetration and delayed market withdrawal.</p>
<a id="article1.body1.sec1.p3" name="article1.body1.sec1.p3"></a><p>In this study, we elucidate long-term temporal trends in rates of inpatient visits for MI to an integrated health system in Boston, Massachusetts and their correspondence with prescriptions for rofecoxib and celecoxib. We estimate the magnitude of this effect on macro-level trends in hospitalizations for MI.</p>
</div>

<div id="section2" class="section"><a id="s2" name="s2" toc="s2" title="Methods"></a><h3>Methods</h3>
<h4>Study Setting and Population</h4>
<a id="article1.body1.sec2.sec1.p1" name="article1.body1.sec2.sec1.p1"></a><p>The patient population was from Partners Healthcare System, a large multi-specialty group practice that provides care to members of a New England–based health maintenance organization. This non-profit, integrated health system includes Brigham and Women's Hospital and Massachusetts General Hospital. The source of clinical data—patient demographic information, dates, medication, and diagnosis information, and discharge summaries—was the Research Patient Data Registry (RPDR), a centralized data warehouse. Institutional Review Board (IRB) approval was obtained.</p>
<a id="article1.body1.sec2.sec1.p2" name="article1.body1.sec2.sec1.p2"></a><p>The study outcome was serious coronary heart disease, defined as acute MI requiring hospitalization. Subjects were all patients hospitalized for MI assigned by primary or admitting diagnosis International Classification of Diseases, Ninth Revision (ICD-9) code 410, from January 1 1997 to March 31 2006. This diagnostic code has been validated by others and used as an indicator of acute MI. <a href="#pone.0000840-Graham1">[10]</a>, <a href="#pone.0000840-Rawson1">[18]</a>, <a href="#pone.0000840-Kiyota1">[19]</a> In our own chart review, we found that 87% of patients assigned the code had strong confirmatory evidence of acute MI. To calculate incidence, we estimated the denominator by combining US Census population estimates for Massachusetts from 1997–2005 with market share estimates for the two study hospitals. Market share was calculated using data from the Massachusetts Division of Health Care Finance and Policy (1999–2004) which contains hospitalizations at all Massachusetts hospitals. Mean yearly market share was estimated at 12.4% (SD, 0.6%). To adjust for biases stemming from shifts in healthcare utilization patterns and changes in health coverage and market share, we also included total number of hospitalizations per unit time as a covariate in our analyses.</p>


<h4>Interrupted Time Series Analysis</h4>
<a id="article1.body1.sec2.sec2.p1" name="article1.body1.sec2.sec2.p1"></a><p>Using a population monitoring framework, we tested for a change in the population rate of MI after introduction of rofecoxib and celecoxib using three time series analysis methods. The first was cumulative sum (CUSUM), regularly used in industrial process control. More recently it has been applied to the early detection of disease outbreaks <a href="#pone.0000840-Hutwagner1">[20]</a> and to adverse drug events.<a href="#pone.0000840-Davis1">[21]</a>, <a href="#pone.0000840-Hauben1">[22]</a> The CUSUM, a type of control chart, detects sudden changes in the mean value of a quantity of interest and provides estimates of the timing and magnitude of change.<a href="#pone.0000840-Williams1">[23]</a> Specifically, the analysis calculates the cumulative sum of deviations from a set value in successive samples. An alarm threshold value is defined a priori taking into account an acceptable false alarm rate or average run length. Here, we used CUSUM to define whether and when a detectable rise in cardiovascular events could have been identified by simply monitoring the time series of monthly rate of inpatient stays for MI.</p>
<a id="article1.body1.sec2.sec2.p2" name="article1.body1.sec2.sec2.p2"></a><p>Second, we investigated the association of the market availability of celecoxib (January 1999–present), and rofecoxib (May 1999–September 2004) on the time series of the monthly rate of inpatient stays for MI using generalized linear modeling. We assumed a Poisson distribution for modeling counts of independent MI events. The model included binary indicator variables for rofecoxib and celecoxib (on or off the market), and used estimated population covered as the offset. Seasonal trends in MIs were adjusted for by including eleven months of the year as indicator variables. We included monthly number of total inpatient stays to adjust for potential secular trends in healthcare utilization. A linear trend term was included to account for long-term changes in MI-related hospitalizations. To account for overdispersion in the count data, extra-Poisson variability was modeled and incorporated into estimates of standard errors.<a href="#pone.0000840-McCullagh1">[24]</a> Parameter estimates were transformed to rate ratios.</p>
<a id="article1.body1.sec2.sec2.p3" name="article1.body1.sec2.sec2.p3"></a><p>Finally, we matched fluctuations in yearly incidence of hospitalizations due to MI to prescription data on rofecoxib and celecoxib. Total numbers of prescriptions dispensed were obtained from the freely available IMS Health annual report on Commonly Requested Therapeutic Class and Product Information.<a href="#pone.0000840-IMS1">[25]</a> We measured the impact of celecoxib and rofecoxib prescription rates by fitting Poisson regression models as described above. In this case, we modeled yearly counts of MIs, including total underlying population as an offset, and overall number of yearly inpatient stays as a model covariate. A linear trend term was included to account for long-term secular trends.<a href="#pone.0000840-Gerber1">[26]</a> Prescription counts for celecoxib and rofecoxib were examined separately and in combination. In addition to incidence, we also examined the association between yearly changes in the mean patient age at time of MI with prescription volume for rofecoxib. All analyses were carried out using the SAS statistical software (version 9.0, SAS Institute Inc., Cary, NC).</p>


<h4>Anchor Diagnoses</h4>
<a id="article1.body1.sec2.sec3.p1" name="article1.body1.sec2.sec3.p1"></a><p>To confirm that our results were not simply reflective of systematic bias related to referral patterns and secular trends in acuity mix at the two hospitals, we monitored yearly changes in three anchor diagnoses. We investigated whether yearly incidence of hospitalizations due to abdominal aortic aneurysm (ICD-9 codes 441.3–441.4), appendicitis (ICD-9 codes 441.3–441.4), and pneumonia and influenza (ICD-9 codes 480–487) were coincident with MIs by two-tailed Spearman rank correlation.</p>

</div>

<div id="section3" class="section"><a id="s3" name="s3" toc="s3" title="Results"></a><h3>Results</h3>
<h4>Study Population</h4>
<a id="article1.body1.sec3.sec1.p1" name="article1.body1.sec3.sec1.p1"></a><p>We identified 25,486 unique patients who had 30,603 MI-related hospitalizations during the study period. Monthly incidence of hospitalizations due to MI ranged from 33.3 per 100,000 inpatient stays in March of 2006 to 56.4 per 100,000 in December, 2002 (mean, 46.2; 95 percent confidence interval, 45.1 to 47.2). Incidence of hospitalizations due to MI ranged from 48.8 per 10,000 in 1997 and 2005 to 62.3 per 10,000 in 2001.</p>


<h4>Interrupted Time Series Analysis</h4>
<a id="article1.body1.sec3.sec2.p1" name="article1.body1.sec3.sec2.p1"></a><p>Based on the mean and standard deviation of MI incidence for a baseline period of 1997–1998, we first tested for cumulating deviations above a target mean of 47.1 MI-related hospitalizations per 100,000 and a standard deviation of 2.8 per 100,000. (<a href="#pone-0000840-g001">Figure 1</a>) The threshold for CUSUM was calculated as 1.18, yielding an average-run-length of 50. In other words, we set the false alarm rate to once per 50 months. An aberration of two standard deviations from baseline was initially detected in January of 2000, with a CUSUM value of 1.37 and 51.5 MI-related hospitalizations per 100,000 stays (9.3 percent above expected). This significant rise was eight months after the market introduction of rofecoxib and one year after the introduction of celecoxib. A second and sustained rise began November of 2000 with a CUSUM value of 2.08 and 54.2 MI-related hospitalizations per 100,000 (16 percent above expected). The exceedance peaked in March of 2003, 46 months after the introduction of rofecoxib with a CUSUM value of 16.5. Threshold was exceeded for 48 consecutive months, ending in October 2004, one month after the market withdrawal of rofecoxib.</p>
<div class="figure" id="pone-0000840-g001"><div class="img"><a name="pone-0000840-g001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000840.g001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000840" data-uri="info:doi/10.1371/journal.pone.0000840.g001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000840.g001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000840.g001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000840.g001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000840.g001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000840.g001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000840.g001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000840.g001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000840.g001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000840.g001.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 1.  <span>Cumulative sum (CUSUM) chart of monthly incidence of hospitalizations due to myocardial infarction from January 1, 1997 to March 30, 2006.</span></strong></p><a id="article1.body1.sec3.sec2.fig1.caption1.p1" name="article1.body1.sec3.sec2.fig1.caption1.p1"></a><p>Assigning 1997 and 1998 as a baseline period, a target mean of 47.1 hospitalizations due to myocardial infarctions per 100,000 and a standard deviation of 2.8 per 100,000.The threshold for CUSUM was calculated as 1.18, yielding an average-run-length of 50 (dashed red line). An aberration, two standard deviations from baseline, was initially detected in January of 2000, with a CUSUM value of 1.37 and 51.5 myocardial infarction-related hospitalization per 100,000 stays (solid line).</p>
<span>doi:10.1371/journal.pone.0000840.g001</span></div><a id="article1.body1.sec3.sec2.p2" name="article1.body1.sec3.sec2.p2"></a><p>Second, we modeled the impact of market availability of celecoxib and rofecoxib on inpatient stays for MIs. For celecoxib, inpatient stays due to MI were 41.6 per 100,000 prior to the December 1999 release (n = 24 months; 95 percent confidence interval, 40.4 to 42.8), and 47.4 from January 1999 to March 2006 (n = 87 months; 95 percent confidence interval. 46.3 to 48.6). MI-related hospitalizations were 41.7 per 100,000 over the period prior to rofecoxib introduction and post-withdrawal (n = 47 months; 95 percent confidence interval, 40.7 to 42.7). While rofecoxib was on the market, the rate of MI-related hospitalizations was 49.4 per 100,000 (n = 64 months; 95 percent confidence interval. 48.3 to 50.5), an 18.5 percent increase. We measured the effect of celecoxib and rofecoxib dispensing on the time series of MI-related hospitalizations by Poisson regression where the two drugs were included as indicator variables. The model for rofecoxib revealed a positive relationship with counts of MIs (rate ratio 1.14; 95 percent confidence interval, 1.09 to 1.19; P&lt;0.001), explaining 28.7 percent of the deviance. The model for celecoxib also revealed a significant positive relationship with counts of MIs (rate ratio 1.09; 95 percent confidence interval, 1.01 to 1.18; P = 0.022), explaining 5.2 percent of the deviance.</p>
<a id="article1.body1.sec3.sec2.p3" name="article1.body1.sec3.sec2.p3"></a><p>Finally, we measured the yearly impact of estimated celecoxib and rofecoxib use on hospitalizations due to MIs as a dose-response relationship using national prescription data (<a href="#pone-0000840-t001">Table 1</a>). Prescriptions for celecoxib and rofecoxib peaked in 2001 with 25.41 and 27.06 million prescriptions dispensed nationally, respectively. Incidence of MI-related hospitalizations also peaked in 2001 with 62.3 hospitalizations per 10,000 (<a href="#pone-0000840-g002">Figure 2</a>). Yearly counts of MIs were significantly predicted by prescriptions for rofecoxib (0.7% increase in MIs per million prescriptions; 95 percent confidence interval, 0.2% to 1.3%) and marginally for celecoxib (0.6% increase in MIs per million prescriptions, 95 percent confidence interval, −0.005% to 1.8%;). For every million prescriptions of both rofecoxib and celecoxib, we found a 0.5 percent increase in MI (95 percent confidence interval, 0.1 to 0.9), explaining approximately 50.3 percent of the deviance in yearly variation of MI-related hospitalizations.</p>
<div class="figure" id="pone-0000840-g002"><div class="img"><a name="pone-0000840-g002" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000840.g002&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000840" data-uri="info:doi/10.1371/journal.pone.0000840.g002"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000840.g002&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000840.g002/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000840.g002/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000840.g002/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000840.g002/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000840.g002.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000840.g002/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000840.g002/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000840.g002.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 2.  <span>Association between yearly prescriptions for rofecoxib and celecoxib and incidence of myocardial infarctions.</span></strong></p><a id="article1.body1.sec3.sec2.fig2.caption1.p1" name="article1.body1.sec3.sec2.fig2.caption1.p1"></a><p>A) Scatter plot reveals the positive relationship between national prescriptions estimates for rofecoxib and celecoxib and hospitalizations due to myocardial infarction. Prescriptions for rofecoxib and celecoxib peaked in 2001 with 52,466,000. Incidence of stays due to myocardial infarction also peaked in 2001 with 62.3 hospitalizations per 10,000. B) Line graphs show the interrupted time series of myocardial infarction-related hospitalizations. Prescriptions for rofecoxib and celecoxib explained approximately 50.3 percent of the deviance in yearly variation of myocardial infarction related hospitalizations.</p>
<span>doi:10.1371/journal.pone.0000840.g002</span></div><div class="figure" id="pone-0000840-t001"><div class="img"><a name="pone-0000840-t001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000840.t001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000840" data-uri="info:doi/10.1371/journal.pone.0000840.t001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000840.t001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000840.t001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000840.t001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000840.t001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000840.t001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000840.t001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000840.t001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000840.t001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000840.t001.TIF"></span>)
                </a></li></ul></div><p><strong>Table 1.  <span>Yearly incidence in hospitalizations due to myocardial infarctions and corresponding national estimates of prescriptions for rofecoxib and celecoxib.</span></strong></p><span>doi:10.1371/journal.pone.0000840.t001</span></div><a id="article1.body1.sec3.sec2.p4" name="article1.body1.sec3.sec2.p4"></a><p>We also find a significant negative association between mean patient age and prescriptions for celecoxib and rofecoxib (Spearman correlation, −0.67, P&lt;0.05). Over the years when rofecoxib was not available, the mean age was 66.5 compared to a mean age of 65.4 over the period of market availability. <a href="#pone-0000840-g003">Figure 3</a> shows the nadir in age corresponding to the peak of rofecoxib and celecoxib prescriptions.</p>
<div class="figure" id="pone-0000840-g003"><div class="img"><a name="pone-0000840-g003" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000840.g003&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000840" data-uri="info:doi/10.1371/journal.pone.0000840.g003"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000840.g003&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000840.g003/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000840.g003/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000840.g003/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000840.g003/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000840.g003.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000840.g003/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000840.g003/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000840.g003.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 3.  <span>Association between yearly prescriptions for rofecoxib and celecoxib and mean age of patients hospitalized for myocardial infarctions.</span></strong></p><a id="article1.body1.sec3.sec2.fig3.caption1.p1" name="article1.body1.sec3.sec2.fig3.caption1.p1"></a><p>Line graph showing a significant negative association between mean patient age and national prescription volume for rofecoxib and celecoxib (Spearman correlation, 0.67, P&lt;0.05). Prescriptions for rofecoxib and celecoxib peaked in 2001 with 27,060,000 prescriptions dispensed nationally while mean age was 64.6, the lowest in nine years.</p>
<span>doi:10.1371/journal.pone.0000840.g003</span></div>

<h4>Anchor Diagnoses</h4>
<a id="article1.body1.sec3.sec3.p1" name="article1.body1.sec3.sec3.p1"></a><p>To demonstrate that our findings were not simply based on changing healthcare utilization, we investigated temporal trends for hospitalizations for three other diagnoses. Though showing a positive linear increase, abdominal aortic aneurysm (Spearman correlation, 0.17; P = 0.66), appendicitis (Spearman correlation, 0.11; P = 0.78), and pneumonia and influenza (Spearman correlation, 0.071; P = 0.86) were not associated with trends in MI. Further, only trends in inpatient visits for MI were significantly correlated with national prescription rates for rofecoxib and celecoxib (Spearman correlation 0.93; P&lt;0.001).</p>

</div>

<div id="section4" class="section"><a id="s4" name="s4" toc="s4" title="Discussion"></a><h3>Discussion</h3><a id="article1.body1.sec4.p1" name="article1.body1.sec4.p1"></a><p>Our findings demonstrate striking longitudinal trends in the population rate of MI and strongly suggest a population-level impact of rofecoxib and celecoxib on MI. Temporal trends in inpatient stays due to MIs are tightly coupled to the rise and fall of prescription of COX-2 inhibitors, with an 18.5 percent increase in inpatient stays for MI during the time when rofecoxib was on the market. These results are consistent with prior reports demonstrating cardiovascular effects of rofecoxib and celecoxib. <a href="#pone.0000840-Kearney1">[9]</a>, <a href="#pone.0000840-Graham1">[10]</a>, <a href="#pone.0000840-HippisleyCox1">[11]</a>, <a href="#pone.0000840-Solomon1">[12]</a>, <a href="#pone.0000840-Caldwell1">[13]</a>, <a href="#pone.0000840-Solomon2">[14]</a>, <a href="#pone.0000840-Nussmeier1">[15]</a>, <a href="#pone.0000840-Bresalier1">[17]</a>, <a href="#pone.0000840-Levesque1">[27]</a> Further, mean age at MI appears to have been lowered by use of these medications.</p>
<a id="article1.body1.sec4.p2" name="article1.body1.sec4.p2"></a><p>Using population surveillance methods <a href="#pone.0000840-Mandl1">[28]</a>, <a href="#pone.0000840-Reis1">[29]</a>, <a href="#pone.0000840-Tsui1">[30]</a> we confirm a sharp rise in adverse cardiovascular events within eight months of the market introduction of rofecoxib and one year after launching of celecoxib. A second rise in November 2000 occurred during the same month as the publication of the Vioxx Gastrointestinal Outcomes Research (VIGOR) study.<a href="#pone.0000840-Bombardier1">[31]</a>, <a href="#pone.0000840-Curfman1">[32]</a> The exceedence vanished within one month of the withdrawal of rofecoxib. The population-level findings, though based on aggregated data, are used to confirm a hypothesis based on clinical trial data <a href="#pone.0000840-Mukherjee1">[16]</a> and to estimate the magnitude of the effect across the population.</p>
<a id="article1.body1.sec4.p3" name="article1.body1.sec4.p3"></a><p>We used two approaches to identify the impact of the prescriptions for COX-2 selective inhibitors. The first was to simply treat each drug as a binary (present or absent) variable. We find increases in inpatients stays for MI after the introduction of rofecoxib and celecoxib. Second, we applied a correlational approach to identify a dose-response relationship by modeling the temporal fluctuations in inpatient stay for MIs with national prescription rates. We find that adverse cardiovascular events coincide best with the time period of population exposure to rofecoxib and celecoxib. The analyses described are subject to the known pitfalls of ecological studies, with caveats about inferring causality.<a href="#pone.0000840-Milane1">[33]</a>, <a href="#pone.0000840-Baune1">[34]</a> However, our results are especially convincing given the return to baseline following the market withdrawal of rofecoxib and our confirmatory analysis. Further, this ecological finding is confirming a prior suspected association.</p>
<a id="article1.body1.sec4.p4" name="article1.body1.sec4.p4"></a><p>Our study does have limitations. Our results, based only on an inpatient population, may underestimate population-level rates of MI. In our analysis, we treated individual patients as independent observations, narrowing confidence intervals for our rate ratio estimates. However, these error calculations do not account for the clustering of responses associated with temporal variation in risk. The IMS prescription data were based on national estimates and may not accurately represent possible local variation in Boston. For instance, geographic variation in prescription practices for rofecoxib and celecoxib may have been disproportionately affected by media attention regarding early reports of associated adverse cardiovascular events. However, our use of yearly estimates should smooth this potential bias. The prescription estimates also do not account for continued use of the drug after its withdrawal from the market.</p>
<a id="article1.body1.sec4.p5" name="article1.body1.sec4.p5"></a><p>While part of the power of this approach stems from availability of the full interrupted time series, including the period after market withdrawal of rofecoxib, our findings highlight the importance of understanding, modeling, and surveying for baseline adverse outcomes to detect population-level aberrations from that baseline. This study was performed with data from only two hospitals a in single health care system, in a single city. In an active post launch surveillance system, such signals will need to be rapidly evaluated and adjudicated with replication in other data sets, in other regions, and through multi-signal integration approaches.</p>
<a id="article1.body1.sec4.p6" name="article1.body1.sec4.p6"></a><p>High profile failures to detect safety problems during the pre-approval period have brought new intense scrutiny on the drug approval process.<a href="#pone.0000840-Psaty1">[35]</a>, <a href="#pone.0000840-Topol1">[36]</a>, <a href="#pone.0000840-Waxman1">[37]</a>, <a href="#pone.0000840-Nissen1">[38]</a>, <a href="#pone.0000840-Psaty2">[39]</a> Revelation of an association between rofecoxib and MI <a href="#pone.0000840-Curfman1">[32]</a>, <a href="#pone.0000840-Psaty1">[35]</a>, <a href="#pone.0000840-Avorn1">[40]</a>, <a href="#pone.0000840-Drazen1">[41]</a> was a signal event highlighting catastrophic failures in monitoring the safety of therapeutics already on the market.<a href="#pone.0000840-IOM1">[42]</a> Because adverse effects of drugs and therapeutics are often not detected in Phase III clinical trials, <a href="#pone.0000840-Ray1">[43]</a> or they are suspected but not confirmed, a robust drug safety system requires ongoing monitoring of adverse events throughout the drug development lifecycle.<a href="#pone.0000840-Crawford1">[44]</a> However, at present, safety efforts are not balanced across the lifecycle.</p>
<a id="article1.body1.sec4.p7" name="article1.body1.sec4.p7"></a><p>There is no generally accepted process or gold standard set of methods for identifying safety problems with drugs during the post launch phase. A major vehicle for hypothesis generation is the FDA's Adverse Event Reporting System (AERS) which collects voluntary reports<a href="#pone.0000840-Food1">[45]</a> that are somewhat limited by poor quality, under-reporting, and skewed and inadequate ascertainment.<a href="#pone.0000840-Heeley1">[46]</a>, <a href="#pone.0000840-Mann1">[47]</a>, <a href="#pone.0000840-Moore1">[48]</a>, <a href="#pone.0000840-Strom1">[49]</a> Nonetheless, AERS-based findings are often the only basis for regulatory action.<a href="#pone.0000840-Strom1">[49]</a>, <a href="#pone.0000840-Psaty3">[50]</a>, <a href="#pone.0000840-Zhou1">[51]</a> Ultimately, however, it impossible to correct for inherent data limitations.</p>
<a id="article1.body1.sec4.p8" name="article1.body1.sec4.p8"></a><p>Notably, in the earlier part of the decade, it would have been very unlikely that a clinician would associate a MI with rofecoxib and hence to report it to the AERS system. Likewise, a clinician would have been unlikely to report a hip fracture in a patient taking a proton pump inhibitor.<a href="#pone.0000840-Yang1">[52]</a> There is an emerging consensus that semi-automated analysis of healthcare databases is the next logical step.<a href="#pone.0000840-Davis1">[21]</a>, <a href="#pone.0000840-Hauben1">[22]</a> Robust post-marketing surveillance requires a multimodality approach to monitoring the health of individuals using drugs and devices. As confirmatory evidence for the veracity of a suspected association, use of a population monitoring approach as an adjunct to pharmacovigilence methods might have helped provide earlier support for the market withdrawal of rofecoxib. Without a known prior association, population health monitoring could help generate hypotheses about candidate medication risk factors. This is especially important for widely prescribed medications where there is a substantial risk of population-level effects. If used prospectively, however, to look across drugs at patterns of prescribing and outcomes, careful attention would need to be paid to issues of specificity and multiple testing.</p>
</div>





<div><a id="ack" name="ack" toc="ack" title="Acknowledgments"></a><h3>Acknowledgments</h3>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1"></a><p>We thank Drs. Sean Murphy, John Glasser, Susanne Churchill, Paul Biddinger, Ben Reis and Karen Olson for their assistance.</p>
</div><div class="contributions"><a id="authcontrib" name="authcontrib" toc="authcontrib" title="Author Contributions"></a><h3>Author Contributions</h3><p>Conceived and designed the experiments: IK JB KM. Performed the experiments: JB MS. Analyzed the data: JB MS. Wrote the paper: IK JB KM MS.</p></div><div><a id="references" name="references" toc="references" title="References"></a><h3>References</h3><ol class="references"><li><span class="label">1.
              </span><a name="pone.0000840-1" id="pone.0000840-1"></a> (2001) Mortality from coronary heart disease and acute myocardial infarction–United States, 1998. MMWR Morb Mortal Wkly Rep  50: 90–93.  <ul class="find" data-citedArticleID="987196"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Mortality+from+coronary+heart+disease+and+acute+myocardial+infarction%26%23x2013%3BUnited+States%2C+1998.&amp;auth=&amp;atitle=Mortality+from+coronary+heart+disease+and+acute+myocardial+infarction%26%23x2013%3BUnited+States%2C+1998." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Mortality+from+coronary+heart+disease+and+acute+myocardial+infarction%26%23x2013%3BUnited+States%2C+1998." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Mortality+from+coronary+heart+disease+and+acute+myocardial+infarction%26%23x2013%3BUnited+States%2C+1998.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">2.
              </span><a name="pone.0000840-American1" id="pone.0000840-American1"></a>American Heart Association (2005) Heart Disease and Stroke Statistics-2005 Update. Dallas, Texas.  <ul class="find-nolinks"></ul></li><li><span class="label">3.
              </span><a name="pone.0000840-Willich1" id="pone.0000840-Willich1"></a>Willich SN, Lewis M, Lowel H, Arntz HR, Schubert F, et al.  (1993) Physical exertion as a trigger of acute myocardial infarction. Triggers and Mechanisms of Myocardial Infarction Study Group. N Engl J Med  329: 1684–1690.  <ul class="find" data-citedArticleID="987292" data-doi="10.1056/nejm199312023292302"><li><a href="http://dx.doi.org/10.1056/nejm199312023292302" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Physical+exertion+as+a+trigger+of+acute+myocardial+infarction.+Triggers+and+Mechanisms+of+Myocardial+Infarction+Study+Group." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Physical+exertion+as+a+trigger+of+acute+myocardial+infarction.+Triggers+and+Mechanisms+of+Myocardial+Infarction+Study+Group.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">4.
              </span><a name="pone.0000840-Rosenberg1" id="pone.0000840-Rosenberg1"></a>Rosenberg L, Palmer JR, Shapiro S (1990) Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med  322: 213–217.  <ul class="find" data-citedArticleID="987276" data-doi="10.1056/nejm199001253220401"><li><a href="http://dx.doi.org/10.1056/nejm199001253220401" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Decline+in+the+risk+of+myocardial+infarction+among+women+who+stop+smoking." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Decline+in+the+risk+of+myocardial+infarction+among+women+who+stop+smoking.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">5.
              </span><a name="pone.0000840-Hu1" id="pone.0000840-Hu1"></a>Hu FB, Stampfer MJ, Manson JE, Rimm E, Colditz GA, et al.  (1997) Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med  337: 1491–1499.  <ul class="find" data-citedArticleID="987232" data-doi="10.1056/nejm199711203372102"><li><a href="http://dx.doi.org/10.1056/nejm199711203372102" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Dietary+fat+intake+and+the+risk+of+coronary+heart+disease+in+women." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Dietary+fat+intake+and+the+risk+of+coronary+heart+disease+in+women.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">6.
              </span><a name="pone.0000840-Borer1" id="pone.0000840-Borer1"></a>Borer JS, Pouleur H, Abadie E, Follath F, Wittes J, et al.  (2007) Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J.   <ul class="find" data-citedArticleID="987206" data-doi="10.1093/eurheartj/ehm209"><li><a href="http://dx.doi.org/10.1093/eurheartj/ehm209" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Cardiovascular+safety+of+drugs+not+intended+for+cardiovascular+use%3A+need+for+a+new+conceptual+basis+for+assessment+and+approval." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Cardiovascular+safety+of+drugs+not+intended+for+cardiovascular+use%3A+need+for+a+new+conceptual+basis+for+assessment+and+approval.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">7.
              </span><a name="pone.0000840-Jick1" id="pone.0000840-Jick1"></a>Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, et al.  (1998) A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med  339: 719–724.  <ul class="find" data-citedArticleID="987240" data-doi="10.1056/nejm199809103391102"><li><a href="http://dx.doi.org/10.1056/nejm199809103391102" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=A+population-based+study+of+appetite-suppressant+drugs+and+the+risk+of+cardiac-valve+regurgitation." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22A+population-based+study+of+appetite-suppressant+drugs+and+the+risk+of+cardiac-valve+regurgitation.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">8.
              </span><a name="pone.0000840-Wysowski1" id="pone.0000840-Wysowski1"></a>Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM (2001) Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol  96: 1698–1703.  <ul class="find" data-citedArticleID="987294"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Postmarketing+reports+of+QT+prolongation+and+ventricular+arrhythmia+in+association+with+cisapride+and+Food+and+Drug+Administration+regulatory+actions.&amp;auth=&amp;atitle=Postmarketing+reports+of+QT+prolongation+and+ventricular+arrhythmia+in+association+with+cisapride+and+Food+and+Drug+Administration+regulatory+actions." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Postmarketing+reports+of+QT+prolongation+and+ventricular+arrhythmia+in+association+with+cisapride+and+Food+and+Drug+Administration+regulatory+actions." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Postmarketing+reports+of+QT+prolongation+and+ventricular+arrhythmia+in+association+with+cisapride+and+Food+and+Drug+Administration+regulatory+actions.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">9.
              </span><a name="pone.0000840-Kearney1" id="pone.0000840-Kearney1"></a>Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, et al.  (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Bmj  332: 1302–1308.  <ul class="find" data-citedArticleID="987242" data-doi="10.1136/bmj.332.7553.1302"><li><a href="http://dx.doi.org/10.1136/bmj.332.7553.1302" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Do+selective+cyclo-oxygenase-2+inhibitors+and+traditional+non-steroidal+anti-inflammatory+drugs+increase+the+risk+of+atherothrombosis%3F+Meta-analysis+of+randomised+trials." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Do+selective+cyclo-oxygenase-2+inhibitors+and+traditional+non-steroidal+anti-inflammatory+drugs+increase+the+risk+of+atherothrombosis%3F+Meta-analysis+of+randomised+trials.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">10.
              </span><a name="pone.0000840-Graham1" id="pone.0000840-Graham1"></a>Graham DJ, Campen D, Hui R, Spence M, Cheetham C, et al.  (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet  365: 475–481.  <ul class="find" data-citedArticleID="987224" data-doi="10.1016/s0140-6736(05)70270-1"><li><a href="http://dx.doi.org/10.1016/s0140-6736(05)70270-1" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Risk+of+acute+myocardial+infarction+and+sudden+cardiac+death+in+patients+treated+with+cyclo-oxygenase+2+selective+and+non-selective+non-steroidal+anti-inflammatory+drugs%3A+nested+case-control+study." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Risk+of+acute+myocardial+infarction+and+sudden+cardiac+death+in+patients+treated+with+cyclo-oxygenase+2+selective+and+non-selective+non-steroidal+anti-inflammatory+drugs%3A+nested+case-control+study.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">11.
              </span><a name="pone.0000840-HippisleyCox1" id="pone.0000840-HippisleyCox1"></a>Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Bmj  330: 1366.  <ul class="find" data-citedArticleID="987230" data-doi="10.1136/bmj.330.7504.1366"><li><a href="http://dx.doi.org/10.1136/bmj.330.7504.1366" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Risk+of+myocardial+infarction+in+patients+taking+cyclo-oxygenase-2+inhibitors+or+conventional+non-steroidal+anti-inflammatory+drugs%3A+population+based+nested+case-control+analysis." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Risk+of+myocardial+infarction+in+patients+taking+cyclo-oxygenase-2+inhibitors+or+conventional+non-steroidal+anti-inflammatory+drugs%3A+population+based+nested+case-control+analysis.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">12.
              </span><a name="pone.0000840-Solomon1" id="pone.0000840-Solomon1"></a>Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, et al.  (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation  109: 2068–2073.  <ul class="find" data-citedArticleID="987278" data-doi="10.1161/01.cir.0000127578.21885.3e"><li><a href="http://dx.doi.org/10.1161/01.cir.0000127578.21885.3e" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Relationship+between+selective+cyclooxygenase-2+inhibitors+and+acute+myocardial+infarction+in+older+adults." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Relationship+between+selective+cyclooxygenase-2+inhibitors+and+acute+myocardial+infarction+in+older+adults.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">13.
              </span><a name="pone.0000840-Caldwell1" id="pone.0000840-Caldwell1"></a>Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R (2006) Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med  99: 132–140.  <ul class="find" data-citedArticleID="987210"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Risk+of+cardiovascular+events+and+celecoxib%3A+a+systematic+review+and+meta-analysis.&amp;auth=&amp;atitle=Risk+of+cardiovascular+events+and+celecoxib%3A+a+systematic+review+and+meta-analysis." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Risk+of+cardiovascular+events+and+celecoxib%3A+a+systematic+review+and+meta-analysis." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Risk+of+cardiovascular+events+and+celecoxib%3A+a+systematic+review+and+meta-analysis.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">14.
              </span><a name="pone.0000840-Solomon2" id="pone.0000840-Solomon2"></a>Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, et al.  (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med  352: 1071–1080.  <ul class="find" data-citedArticleID="987280" data-doi="10.1056/nejmoa050405"><li><a href="http://dx.doi.org/10.1056/nejmoa050405" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Cardiovascular+risk+associated+with+celecoxib+in+a+clinical+trial+for+colorectal+adenoma+prevention." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Cardiovascular+risk+associated+with+celecoxib+in+a+clinical+trial+for+colorectal+adenoma+prevention.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">15.
              </span><a name="pone.0000840-Nussmeier1" id="pone.0000840-Nussmeier1"></a>Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, et al.  (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med  352: 1081–1091.  <ul class="find" data-citedArticleID="987262" data-doi="10.1056/nejmoa050330"><li><a href="http://dx.doi.org/10.1056/nejmoa050330" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Complications+of+the+COX-2+inhibitors+parecoxib+and+valdecoxib+after+cardiac+surgery." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Complications+of+the+COX-2+inhibitors+parecoxib+and+valdecoxib+after+cardiac+surgery.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">16.
              </span><a name="pone.0000840-Mukherjee1" id="pone.0000840-Mukherjee1"></a>Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. Jama  286: 954–959.  <ul class="find" data-citedArticleID="987258" data-doi="10.1001/jama.286.8.954"><li><a href="http://dx.doi.org/10.1001/jama.286.8.954" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Risk+of+cardiovascular+events+associated+with+selective+COX-2+inhibitors." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Risk+of+cardiovascular+events+associated+with+selective+COX-2+inhibitors.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">17.
              </span><a name="pone.0000840-Bresalier1" id="pone.0000840-Bresalier1"></a>Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al.  (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med  352: 1092–1102.  <ul class="find" data-citedArticleID="987208" data-doi="10.1056/nejmoa050493"><li><a href="http://dx.doi.org/10.1056/nejmoa050493" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Cardiovascular+events+associated+with+rofecoxib+in+a+colorectal+adenoma+chemoprevention+trial." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Cardiovascular+events+associated+with+rofecoxib+in+a+colorectal+adenoma+chemoprevention+trial.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">18.
              </span><a name="pone.0000840-Rawson1" id="pone.0000840-Rawson1"></a>Rawson NS, Malcolm E (1995) Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med  14: 2627–2643.  <ul class="find" data-citedArticleID="987270" data-doi="10.1002/sim.4780142404"><li><a href="http://dx.doi.org/10.1002/sim.4780142404" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Validity+of+the+recording+of+ischaemic+heart+disease+and+chronic+obstructive+pulmonary+disease+in+the+Saskatchewan+health+care+datafiles." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Validity+of+the+recording+of+ischaemic+heart+disease+and+chronic+obstructive+pulmonary+disease+in+the+Saskatchewan+health+care+datafiles.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">19.
              </span><a name="pone.0000840-Kiyota1" id="pone.0000840-Kiyota1"></a>Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, et al.  (2004) Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J  148: 99–104.  <ul class="find" data-citedArticleID="987244" data-doi="10.1016/j.ahj.2004.02.013"><li><a href="http://dx.doi.org/10.1016/j.ahj.2004.02.013" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Accuracy+of+Medicare+claims-based+diagnosis+of+acute+myocardial+infarction%3A+estimating+positive+predictive+value+on+the+basis+of+review+of+hospital+records." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Accuracy+of+Medicare+claims-based+diagnosis+of+acute+myocardial+infarction%3A+estimating+positive+predictive+value+on+the+basis+of+review+of+hospital+records.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">20.
              </span><a name="pone.0000840-Hutwagner1" id="pone.0000840-Hutwagner1"></a>Hutwagner LC, Maloney EK, Bean NH, Slutsker L, Martin SM (1997) Using laboratory-based surveillance data for prevention: an algorithm for detecting Salmonella outbreaks. Emerg Infect Dis  3: 395–400.  <ul class="find" data-citedArticleID="987234" data-doi="10.3201/eid0303.970322"><li><a href="http://dx.doi.org/10.3201/eid0303.970322" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Using+laboratory-based+surveillance+data+for+prevention%3A+an+algorithm+for+detecting+Salmonella+outbreaks." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Using+laboratory-based+surveillance+data+for+prevention%3A+an+algorithm+for+detecting+Salmonella+outbreaks.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">21.
              </span><a name="pone.0000840-Davis1" id="pone.0000840-Davis1"></a>Davis RL, Kolczak M, Lewis E, Nordin J, Goodman M, et al.  (2005) Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology  16: 336–341.  <ul class="find" data-citedArticleID="987216" data-doi="10.1097/01.ede.0000155506.05636.a4"><li><a href="http://dx.doi.org/10.1097/01.ede.0000155506.05636.a4" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Active+surveillance+of+vaccine+safety%3A+a+system+to+detect+early+signs+of+adverse+events." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Active+surveillance+of+vaccine+safety%3A+a+system+to+detect+early+signs+of+adverse+events.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">22.
              </span><a name="pone.0000840-Hauben1" id="pone.0000840-Hauben1"></a>Hauben M, Zhou X (2003) Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf  26: 159–186.  <ul class="find" data-citedArticleID="987226" data-doi="10.2165/00002018-200326030-00003"><li><a href="http://dx.doi.org/10.2165/00002018-200326030-00003" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Quantitative+methods+in+pharmacovigilance%3A+focus+on+signal+detection." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Quantitative+methods+in+pharmacovigilance%3A+focus+on+signal+detection.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">23.
              </span><a name="pone.0000840-Williams1" id="pone.0000840-Williams1"></a>Williams SM, Parry BR, Schlup MM (1992) Quality control: an application of the cusum. Bmj  304: 1359–1361.  <ul class="find" data-citedArticleID="987290" data-doi="10.1136/bmj.304.6838.1359"><li><a href="http://dx.doi.org/10.1136/bmj.304.6838.1359" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Quality+control%3A+an+application+of+the+cusum." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Quality+control%3A+an+application+of+the+cusum.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">24.
              </span><a name="pone.0000840-McCullagh1" id="pone.0000840-McCullagh1"></a>McCullagh P, Nelder JA (1989) Generalized Linear Models. London: Chapman and Hall.   <ul class="find-nolinks"></ul></li><li><span class="label">25.
              </span><a name="pone.0000840-IMS1" id="pone.0000840-IMS1"></a>IMS Health (2006)  Commonly Requested Therapeutic Class and Product Information. In: Health I, editor. IMS Health.   <ul class="find-nolinks"></ul></li><li><span class="label">26.
              </span><a name="pone.0000840-Gerber1" id="pone.0000840-Gerber1"></a>Gerber Y, Jacobsen SJ, Frye RL, Weston SA, Killian JM, et al.  (2006) Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation  113: 2285–2292.  <ul class="find" data-citedArticleID="987222" data-doi="10.1161/circulationaha.105.590463"><li><a href="http://dx.doi.org/10.1161/circulationaha.105.590463" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Secular+trends+in+deaths+from+cardiovascular+diseases%3A+a+25-year+community+study." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Secular+trends+in+deaths+from+cardiovascular+diseases%3A+a+25-year+community+study.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">27.
              </span><a name="pone.0000840-Levesque1" id="pone.0000840-Levesque1"></a>Levesque LE, Brophy JM, Zhang B (2005) The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med  142: 481–489.  <ul class="find" data-citedArticleID="987246" data-doi="10.7326/0003-4819-142-7-200504050-00113"><li><a href="http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00113" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+risk+for+myocardial+infarction+with+cyclooxygenase-2+inhibitors%3A+a+population+study+of+elderly+adults." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+risk+for+myocardial+infarction+with+cyclooxygenase-2+inhibitors%3A+a+population+study+of+elderly+adults.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">28.
              </span><a name="pone.0000840-Mandl1" id="pone.0000840-Mandl1"></a>Mandl KD, Overhage JM, Wagner MM, Lober WB, Sebastiani P, et al.  (2004) Implementing syndromic surveillance: a practical guide informed by the early experience.  J Am Med Inform Assoc  11: 141–150 [PrePrint published Nov 121, 2003; as doi:2010.1197/jamia.M1356].  <ul class="find" data-citedArticleID="987248"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Implementing+syndromic+surveillance%3A+a+practical+guide+informed+by+the+early+experience.&amp;auth=&amp;atitle=Implementing+syndromic+surveillance%3A+a+practical+guide+informed+by+the+early+experience." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Implementing+syndromic+surveillance%3A+a+practical+guide+informed+by+the+early+experience." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Implementing+syndromic+surveillance%3A+a+practical+guide+informed+by+the+early+experience.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">29.
              </span><a name="pone.0000840-Reis1" id="pone.0000840-Reis1"></a>Reis BY, Pagano M, Mandl KD (2003) Using temporal context to improve biosurveillance. Proc Natl Acad Sci U S A  100: 1961–1965.  <ul class="find" data-citedArticleID="987274" data-doi="10.1073/pnas.0335026100"><li><a href="http://dx.doi.org/10.1073/pnas.0335026100" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Using+temporal+context+to+improve+biosurveillance." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Using+temporal+context+to+improve+biosurveillance.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">30.
              </span><a name="pone.0000840-Tsui1" id="pone.0000840-Tsui1"></a>Tsui FC, Espino JU, Dato VM, Gesteland PH, Hutman J, et al.  (2003) Technical description of RODS: a real-time public health surveillance system. J Am Med Inform Assoc  10: 399–408.  <ul class="find" data-citedArticleID="987286"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Technical+description+of+RODS%3A+a+real-time+public+health+surveillance+system.&amp;auth=&amp;atitle=Technical+description+of+RODS%3A+a+real-time+public+health+surveillance+system." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Technical+description+of+RODS%3A+a+real-time+public+health+surveillance+system." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Technical+description+of+RODS%3A+a+real-time+public+health+surveillance+system.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">31.
              </span><a name="pone.0000840-Bombardier1" id="pone.0000840-Bombardier1"></a>Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al.  (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med  343: 1520–1528, 1522 p following 1528.  <ul class="find" data-citedArticleID="987204" data-doi="10.1056/nejm200011233432103"><li><a href="http://dx.doi.org/10.1056/nejm200011233432103" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Comparison+of+upper+gastrointestinal+toxicity+of+rofecoxib+and+naproxen+in+patients+with+rheumatoid+arthritis.+VIGOR+Study+Group." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Comparison+of+upper+gastrointestinal+toxicity+of+rofecoxib+and+naproxen+in+patients+with+rheumatoid+arthritis.+VIGOR+Study+Group.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">32.
              </span><a name="pone.0000840-Curfman1" id="pone.0000840-Curfman1"></a>Curfman GD, Morrissey S, Drazen JM (2005) Expression of concern: Bombardier et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” N Engl J Med 2000;343:1520-8. N Engl J Med  353: 2813–2814.  <ul class="find" data-citedArticleID="987214" data-doi="10.1056/nejme058314"><li><a href="http://dx.doi.org/10.1056/nejme058314" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Expression+of+concern%3A+Bombardier+et+al.%2C+%26%23x201c%3BComparison+of+upper+gastrointestinal+toxicity+of+rofecoxib+and+naproxen+in+patients+with+rheumatoid+arthritis%2C%26%23x201d%3B+N+Engl+J+Med+2000%3B343%3A1520-8." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Expression+of+concern%3A+Bombardier+et+al.%2C+%26%23x201c%3BComparison+of+upper+gastrointestinal+toxicity+of+rofecoxib+and+naproxen+in+patients+with+rheumatoid+arthritis%2C%26%23x201d%3B+N+Engl+J+Med+2000%3B343%3A1520-8.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">33.
              </span><a name="pone.0000840-Milane1" id="pone.0000840-Milane1"></a>Milane MS, Suchard MA, Wong ML, Licinio J (2006) Modeling of the temporal patterns of fluoxetine prescriptions and suicide rates in the United States. PLoS Med  3: e190.  <ul class="find" data-citedArticleID="987254" data-doi="10.1371/journal.pmed.0030190"><li><a href="http://dx.doi.org/10.1371/journal.pmed.0030190" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Modeling+of+the+temporal+patterns+of+fluoxetine+prescriptions+and+suicide+rates+in+the+United+States." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Modeling+of+the+temporal+patterns+of+fluoxetine+prescriptions+and+suicide+rates+in+the+United+States.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">34.
              </span><a name="pone.0000840-Baune1" id="pone.0000840-Baune1"></a>Baune B, Hay P (2006) Suicide rates and antidepressant prescribing: a casual or causal relationship? PLoS Med  3: e220.  <ul class="find" data-citedArticleID="987202" data-doi="10.1371/journal.pmed.0030220"><li><a href="http://dx.doi.org/10.1371/journal.pmed.0030220" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Suicide+rates+and+antidepressant+prescribing%3A+a+casual+or+causal+relationship%3F" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Suicide+rates+and+antidepressant+prescribing%3A+a+casual+or+causal+relationship%3F%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">35.
              </span><a name="pone.0000840-Psaty1" id="pone.0000840-Psaty1"></a>Psaty BM, Furberg CD (2005) COX-2 inhibitors–lessons in drug safety. N Engl J Med  352: 1133–1135.  <ul class="find" data-citedArticleID="987264" data-doi="10.1056/nejme058042"><li><a href="http://dx.doi.org/10.1056/nejme058042" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=COX-2+inhibitors%26%23x2013%3Blessons+in+drug+safety." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22COX-2+inhibitors%26%23x2013%3Blessons+in+drug+safety.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">36.
              </span><a name="pone.0000840-Topol1" id="pone.0000840-Topol1"></a>Topol EJ (2004) Failing the public health–rofecoxib, Merck, and the FDA. N Engl J Med  351: 1707–1709.  <ul class="find" data-citedArticleID="987284" data-doi="10.1056/nejmp048286"><li><a href="http://dx.doi.org/10.1056/nejmp048286" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Failing+the+public+health%26%23x2013%3Brofecoxib%2C+Merck%2C+and+the+FDA." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Failing+the+public+health%26%23x2013%3Brofecoxib%2C+Merck%2C+and+the+FDA.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">37.
              </span><a name="pone.0000840-Waxman1" id="pone.0000840-Waxman1"></a>Waxman HA (2005) The lessons of Vioxx–drug safety and sales. N Engl J Med  352: 2576–2578.  <ul class="find" data-citedArticleID="987288" data-doi="10.1056/nejmp058136"><li><a href="http://dx.doi.org/10.1056/nejmp058136" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+lessons+of+Vioxx%26%23x2013%3Bdrug+safety+and+sales." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+lessons+of+Vioxx%26%23x2013%3Bdrug+safety+and+sales.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">38.
              </span><a name="pone.0000840-Nissen1" id="pone.0000840-Nissen1"></a>Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med  356: 2457–2471.  <ul class="find" data-citedArticleID="987260" data-doi="10.1056/nejmoa072761"><li><a href="http://dx.doi.org/10.1056/nejmoa072761" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Effect+of+rosiglitazone+on+the+risk+of+myocardial+infarction+and+death+from+cardiovascular+causes." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Effect+of+rosiglitazone+on+the+risk+of+myocardial+infarction+and+death+from+cardiovascular+causes.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">39.
              </span><a name="pone.0000840-Psaty2" id="pone.0000840-Psaty2"></a>Psaty BM, Furberg CD (2007) Rosiglitazone and cardiovascular risk. N Engl J Med  356: 2522–2524.  <ul class="find" data-citedArticleID="987266" data-doi="10.1056/nejme078099"><li><a href="http://dx.doi.org/10.1056/nejme078099" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Rosiglitazone+and+cardiovascular+risk." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Rosiglitazone+and+cardiovascular+risk.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">40.
              </span><a name="pone.0000840-Avorn1" id="pone.0000840-Avorn1"></a>Avorn J (2006) Evaluating drug effects in the post-Vioxx world: there must be a better way. Circulation  113: 2173–2176.  <ul class="find" data-citedArticleID="987200" data-doi="10.1161/circulationaha.106.625749"><li><a href="http://dx.doi.org/10.1161/circulationaha.106.625749" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Evaluating+drug+effects+in+the+post-Vioxx+world%3A+there+must+be+a+better+way." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Evaluating+drug+effects+in+the+post-Vioxx+world%3A+there+must+be+a+better+way.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">41.
              </span><a name="pone.0000840-Drazen1" id="pone.0000840-Drazen1"></a>Drazen JM (2005) COX-2 inhibitors–a lesson in unexpected problems. N Engl J Med  352: 1131–1132.  <ul class="find" data-citedArticleID="987218" data-doi="10.1056/nejme058038"><li><a href="http://dx.doi.org/10.1056/nejme058038" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=COX-2+inhibitors%26%23x2013%3Ba+lesson+in+unexpected+problems." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22COX-2+inhibitors%26%23x2013%3Ba+lesson+in+unexpected+problems.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">42.
              </span><a name="pone.0000840-IOM1" id="pone.0000840-IOM1"></a>IOM (2006) The Future of Drug Safety: Promoting and Protecting the Health of the Public.   <ul class="find-nolinks"></ul></li><li><span class="label">43.
              </span><a name="pone.0000840-Ray1" id="pone.0000840-Ray1"></a>Ray WA, Stein CM (2006) Reform of drug regulation–beyond an independent drug-safety board. N Engl J Med  354: 194–201.  <ul class="find" data-citedArticleID="987272" data-doi="10.1056/nejmsb053432"><li><a href="http://dx.doi.org/10.1056/nejmsb053432" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Reform+of+drug+regulation%26%23x2013%3Bbeyond+an+independent+drug-safety+board." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Reform+of+drug+regulation%26%23x2013%3Bbeyond+an+independent+drug-safety+board.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">44.
              </span><a name="pone.0000840-Crawford1" id="pone.0000840-Crawford1"></a>Crawford LM (2005) Remarks of the Acting FDA Commissioner: FDLI's 48th annual conference. Food Drug Law J  60: 99–102.  <ul class="find" data-citedArticleID="987212"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Remarks+of+the+Acting+FDA+Commissioner%3A+FDLI%27s+48th+annual+conference.&amp;auth=&amp;atitle=Remarks+of+the+Acting+FDA+Commissioner%3A+FDLI%27s+48th+annual+conference." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Remarks+of+the+Acting+FDA+Commissioner%3A+FDLI%27s+48th+annual+conference." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Remarks+of+the+Acting+FDA+Commissioner%3A+FDLI%27s+48th+annual+conference.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">45.
              </span><a name="pone.0000840-Food1" id="pone.0000840-Food1"></a>Food and Drug Administration (2003) MedWatch Reporting by Consumers.   <ul class="find-nolinks"></ul></li><li><span class="label">46.
              </span><a name="pone.0000840-Heeley1" id="pone.0000840-Heeley1"></a>Heeley E, Riley J, Layton D, Wilton LV, Shakir SA (2001) Prescription-event monitoring and reporting of adverse drug reactions. Lancet  358: 1872–1873.  <ul class="find" data-citedArticleID="987228" data-doi="10.1016/s0140-6736(01)06898-2"><li><a href="http://dx.doi.org/10.1016/s0140-6736(01)06898-2" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Prescription-event+monitoring+and+reporting+of+adverse+drug+reactions." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Prescription-event+monitoring+and+reporting+of+adverse+drug+reactions.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">47.
              </span><a name="pone.0000840-Mann1" id="pone.0000840-Mann1"></a>Mann RD (2004) Assessments of disproportionality. Pharmacoepidemiol Drug Saf  13: 501–502.  <ul class="find" data-citedArticleID="987250" data-doi="10.1002/pds.994"><li><a href="http://dx.doi.org/10.1002/pds.994" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Assessments+of+disproportionality." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Assessments+of+disproportionality.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">48.
              </span><a name="pone.0000840-Moore1" id="pone.0000840-Moore1"></a>Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, et al.  (2003) Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf  12: 271–281.  <ul class="find" data-citedArticleID="987256" data-doi="10.1002/pds.848"><li><a href="http://dx.doi.org/10.1002/pds.848" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Biases+affecting+the+proportional+reporting+ratio+%28PPR%29+in+spontaneous+reports+pharmacovigilance+databases%3A+the+example+of+sertindole." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Biases+affecting+the+proportional+reporting+ratio+%28PPR%29+in+spontaneous+reports+pharmacovigilance+databases%3A+the+example+of+sertindole.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">49.
              </span><a name="pone.0000840-Strom1" id="pone.0000840-Strom1"></a>Strom BL (2004) Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. Jama  292: 2643–2646.  <ul class="find" data-citedArticleID="987282" data-doi="10.1001/jama.292.21.2643"><li><a href="http://dx.doi.org/10.1001/jama.292.21.2643" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Potential+for+conflict+of+interest+in+the+evaluation+of+suspected+adverse+drug+reactions%3A+a+counterpoint." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Potential+for+conflict+of+interest+in+the+evaluation+of+suspected+adverse+drug+reactions%3A+a+counterpoint.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">50.
              </span><a name="pone.0000840-Psaty3" id="pone.0000840-Psaty3"></a>Psaty BM, Furberg CD, Ray WA, Weiss NS (2004) Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. Jama  292: 2622–2631.  <ul class="find" data-citedArticleID="987268" data-doi="10.1001/jama.292.21.2622"><li><a href="http://dx.doi.org/10.1001/jama.292.21.2622" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Potential+for+conflict+of+interest+in+the+evaluation+of+suspected+adverse+drug+reactions%3A+use+of+cerivastatin+and+risk+of+rhabdomyolysis." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Potential+for+conflict+of+interest+in+the+evaluation+of+suspected+adverse+drug+reactions%3A+use+of+cerivastatin+and+risk+of+rhabdomyolysis.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">51.
              </span><a name="pone.0000840-Zhou1" id="pone.0000840-Zhou1"></a>Zhou W, Pool V, DeStefano F, Iskander JK, Haber P, et al.  (2004) A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)–United States, 1991-2001. Pharmacoepidemiol Drug Saf  13: 505–510.  <ul class="find" data-citedArticleID="987298" data-doi="10.1002/pds.998"><li><a href="http://dx.doi.org/10.1002/pds.998" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=A+potential+signal+of+Bell%27s+palsy+after+parenteral+inactivated+influenza+vaccines%3A+reports+to+the+Vaccine+Adverse+Event+Reporting+System+%28VAERS%29%26%23x2013%3BUnited+States%2C+1991-2001." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22A+potential+signal+of+Bell%27s+palsy+after+parenteral+inactivated+influenza+vaccines%3A+reports+to+the+Vaccine+Adverse+Event+Reporting+System+%28VAERS%29%26%23x2013%3BUnited+States%2C+1991-2001.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">52.
              </span><a name="pone.0000840-Yang1" id="pone.0000840-Yang1"></a>Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. Jama  296: 2947–2953.  <ul class="find" data-citedArticleID="987296" data-doi="10.1001/jama.296.24.2947"><li><a href="http://dx.doi.org/10.1001/jama.296.24.2947" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Long-term+proton+pump+inhibitor+therapy+and+risk+of+hip+fracture." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Long-term+proton+pump+inhibitor+therapy+and+risk+of+hip+fracture.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li></ol></div>

  </div>

      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.XML" value="81011"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.PDF" value="218418"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g001.PNG_L" value="49264"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g001.PNG_M" value="69311"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g001.PNG_S" value="7907"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g001.TIF" value="236986"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g001.PNG_I" value="26370"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g002.PNG_L" value="107377"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g002.PNG_M" value="68187"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g002.PNG_S" value="6212"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g002.TIF" value="394566"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g002.PNG_I" value="22994"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.t001.PNG_L" value="170203"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.t001.PNG_M" value="98054"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.t001.PNG_S" value="11010"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.t001.TIF" value="766690"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.t001.PNG_I" value="30725"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g003.PNG_L" value="53503"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g003.PNG_M" value="86620"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g003.PNG_S" value="8682"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g003.TIF" value="245218"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000840.g003.PNG_I" value="32652"/>

</div>
<div class="sidebar">

  <div class="article-actions cf">
      <div class="download">
        <span class="btn"><a href="/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000840&amp;representation=PDF" title="Download" target="_blank">Download PDF</a></span>
      </div>
      <div class="btn-reveal dropdown">
        <div class="dropdown-icon">
          <span class="btn">&nbsp;</span>
        </div>

        <div class="content">
          <ul class="bullet">
            <li><a href="/article/citationList.action?articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000840" title="Download citations">Citation</a></li>
            <li><a href="/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000840&amp;representation=XML" title="Download article XML">XML</a></li>
          </ul>
        </div>
      </div> <!-- end btn-reveal dropdown-->


    <div class="btn-reveal flt-l">
        <span class="btn">Print</span>
        <div class="content">
            <ul class="bullet">
                <li id="print-article"><a href="#" onclick="if(typeof(_gaq) != 'undefined'){ _gaq.push(['_trackEvent','Article', 'Print', 'Click']); } window.print(); return false;" title="Print Article">Print article</a></li>
                <li>
                  <a href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=7&doi=10.1371/journal.pone.0000840&volume=&issue=&title=The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction&author_name=John%20S.%20Brownstein%2C%20Margarita%20Sordo%2C%20Isaac%20S.%20Kohane%2C%20Kenneth%20D.%20Mandl&start_page=1&end_page=6" title="Odyssey Press">EzReprint</a>
                </li>
            </ul>
        </div>
    </div>

    <div class="btn-reveal flt-r">
        <span class="btn">Share</span>
        <div class="content">
            <ul class="social">
                <li><a href="http://www.reddit.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000840" target="_blank" title="Submit to Reddit"><img src="/images/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

                <li><a href="https://plus.google.com/share?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000840" target="_blank" title="Share on Google+"><img src="/images/icon.gplus.16.png" width="16" height="16" alt="Google+">Google+</a></li>

                <li><a href="http://www.stumbleupon.com/submit?url=http%3A%2F%2Fwww.plosone.org%2Farticle%2Finfo%253Adoi%252F10.1371%252Fjournal.pone.0000840" target="_blank" title="Add to StumbleUpon"><img src="/images/icon.stumble.16.png" width="16" height="16" alt="StumbleUpon">StumbleUpon</a></li>

                <li><a href="http://www.facebook.com/share.php?u=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000840&amp;t=The%20Tell-Tale%20Heart%3A%20Population-Based%20Surveillance%20Reveals%20an%20Association%20of%20Rofecoxib%20and%20Celecoxib%20with%20Myocardial%20Infarction" target="_blank" title="Share on Facebook"><img src="/images/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>

                <li><a href="http://www.linkedin.com/shareArticle?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000840&title=The%20Tell-Tale%20Heart%3A%20Population-Based%20Surveillance%20Reveals%20an%20Association%20of%20Rofecoxib%20and%20Celecoxib%20with%20Myocardial%20Infarction&summary=Checkout%20this%20article%20I%20found%20at%20PLOS" target="_blank" title="Add to LinkedIn"><img src="/images/icon.linkedin.16.png" width="16" height="16" alt="Mendeley">LinkedIn</a></li>

                <li><a href="http://www.citeulike.org/posturl?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000840&amp;title=The%20Tell-Tale%20Heart%3A%20Population-Based%20Surveillance%20Reveals%20an%20Association%20of%20Rofecoxib%20and%20Celecoxib%20with%20Myocardial%20Infarction" target="_blank" title="Add to CiteULike"><img src="/images/icon.cul.16.png" width="16" height="16" alt="CiteULike">CiteULike</a></li>

                <li><a href="http://www.mendeley.com/import/?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000840" target="_blank" title="Add to Mendeley"><img src="/images/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

                <li><a href="https://www.pubchase.com/library?add_aid=10.1371%2Fjournal.pone.0000840&amp;source=plos" target="_blank" title="Add to PubChase"><img src="/images/icon.pc.16.png" width="16" height="16" alt="PubChase">PubChase</a></li>


                <script type="text/javascript">
                    // replace tweet with one that's pre-shortened to 140 chars
                    function truncateTweetText() {
                        var twtTitle = 'The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction';
                        var twtUrl = 'http://dx.plos.org/10.1371/journal.pone.0000840';
                        // all URLs posted to twitter get auto-shortened to 20 chars.
                        var maxLength = 140 - (20 + 1);
                        // truncate the title to include space for twtTag and ellipsis (here, 10 = tag length + space + ellipsis)
                        if (twtTitle.length > maxLength) { twtTitle = twtTitle.substr(0, (maxLength - 10)) + '...'; }
                        // set the href to use the shortened tweet
                        $('#twitter-share-link').prop('href', 'http://twitter.com/intent/tweet?text=' + encodeURIComponent('#PLOSONE: ' + twtTitle + ' ' + twtUrl));
                    }
                </script>
                <li><a href="http://twitter.com/intent/tweet?text=#PLOSONE%3A%20The%20Tell-Tale%20Heart%3A%20Population-Based%20Surveillance%20Reveals%20an%20Association%20of%20Rofecoxib%20and%20Celecoxib%20with%20Myocardial%20Infarction http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000840" onclick="truncateTweetText();" target="_blank" title="Share on Twitter" id="twitter-share-link"><img src="/images/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

                <li><a href="/article/email/info%3Adoi%2F10.1371%2Fjournal.pone.0000840" title="Email this article"><img src="/images/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
            </ul>
        </div>
    </div><!--end btn-reveal flt-r-->
</div><!-- end article-actions-->

<!-- begin Crossmark -->

<a id="open-crossmark" href="#" style="margin-top: -28px; display:block"><img style="border: 0; display: none;
 padding: 10px 0 18px 0;"  id="crossmark-icon" src="/images/logo-crossmark-bw.png" /></a>
<div id="crossmark-dialog" style="display: none;" title="">
    <!-- the external CrossMark data is loaded inside this iframe -->
    <iframe id="crossmark-dialog-frame" frameborder="0"></iframe>
</div>

<!-- end crossmark -->


<div class="block" id="subject-area-sidebar-block">
    <div class="header">
        <h3>Subject Areas</h3><div title="More information" id="subject-area-sidebar-block-help-icon"><img align="right"
                                                                                                           alt="info" src="/images/button_info.png"/><div id="subject-area-sidebar-block-help"><img align="right"
                                                                                                                                                                                                    src="/images/button_info.png"/><p>
        <b>We want your feedback.</b> Do these subject areas make sense for this article? If not, click the flag
        next to the incorrect subject area and we will review it. Thanks for your help!
    </p></div></div>
    </div>


    <ul id="subject-area-sidebar-list">









          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22COX-2+inhibitors%22" title="Search for articles in the subject area:'COX-2 inhibitors'"><div class="flagText">COX-2 inhibitors</div></a>
              <div data-categoryid="36461" data-articleid="24518"
                   data-categoryname="COX-2 inhibitors"
                   class="flagImage" title="Flag 'COX-2 inhibitors' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Confidence+intervals%22" title="Search for articles in the subject area:'Confidence intervals'"><div class="flagText">Confidence intervals</div></a>
              <div data-categoryid="32051" data-articleid="24518"
                   data-categoryname="Confidence intervals"
                   class="flagImage" title="Flag 'Confidence intervals' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Diagnostic+medicine%22" title="Search for articles in the subject area:'Diagnostic medicine'"><div class="flagText">Diagnostic medicine</div></a>
              <div data-categoryid="3267" data-articleid="24518"
                   data-categoryname="Diagnostic medicine"
                   class="flagImage" title="Flag 'Diagnostic medicine' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Drug+research+and+development%22" title="Search for articles in the subject area:'Drug research and development'"><div class="flagText">Drug research and development</div></a>
              <div data-categoryid="18001" data-articleid="24518"
                   data-categoryname="Drug research and development"
                   class="flagImage" title="Flag 'Drug research and development' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Drug+therapy%22" title="Search for articles in the subject area:'Drug therapy'"><div class="flagText">Drug therapy</div></a>
              <div data-categoryid="18461" data-articleid="24518"
                   data-categoryname="Drug therapy"
                   class="flagImage" title="Flag 'Drug therapy' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Inpatients%22" title="Search for articles in the subject area:'Inpatients'"><div class="flagText">Inpatients</div></a>
              <div data-categoryid="25985" data-articleid="24518"
                   data-categoryname="Inpatients"
                   class="flagImage" title="Flag 'Inpatients' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Myocardial+infarction%22" title="Search for articles in the subject area:'Myocardial infarction'"><div class="flagText">Myocardial infarction</div></a>
              <div data-categoryid="24301" data-articleid="24518"
                   data-categoryname="Myocardial infarction"
                   class="flagImage" title="Flag 'Myocardial infarction' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Therapeutic+drug+monitoring%22" title="Search for articles in the subject area:'Therapeutic drug monitoring'"><div class="flagText">Therapeutic drug monitoring</div></a>
              <div data-categoryid="30091" data-articleid="24518"
                   data-categoryname="Therapeutic drug monitoring"
                   class="flagImage" title="Flag 'Therapeutic drug monitoring' as inappropriate"></div>
          </li>
    </ul>
</div>

<div class="ad">
    <div class="title">Advertisement</div>






  <iframe id='a0852f54' name='a0852f54'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=381&amp;cb=4100'
    frameborder='0' scrolling='no' width='160' height='600'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a0852f54&amp;cb=2402'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=381&amp;cb=6609&amp;n=a0852f54'
      border='0' alt=''/>
    </a>
  </iframe>



</div>

<div id="twitter-alm-timeline" class="twitter-alm-timeline"></div>


</div><!-- sidebar -->
    </div>
  </div>
</div>
<script src="http://wl.figshare.com/static/p_widget.js" type="text/javascript"></script><div id="pageftr">
  <div class="ftr-cols cf">
    <div class="col col-1">
      <img src="/images/logo-plos-footer.png" alt="PLOS Logo" class="logo" />
      <p><a href="/static/releaseNotes">Ambra 2.9.16</a> Managed Colocation provided <br />by <a href="http://www.isc.org/">Internet Systems Consortium</a>.<p>
      <div class="nav nav-aux">
        <a href="/static/privacy">Privacy Policy</a> |
        <a href="/static/terms">Terms of Use</a> |
        <a href="http://www.plos.org/advertise/">Advertise</a> |
        <a href="http://www.plos.org/about/media-inquiries/">Media Inquiries</a>
      </div>
    </div>
    <div class="col col-2">
      <p><a href="http://www.plos.org/publications/journals/">Publications</a></p>
      <div class="nav">
        <ul>
          <li><a href="http://www.plosbiology.org">PLOS Biology</a></li>
          <li><a href="http://www.plosmedicine.org">PLOS Medicine</a></li>
          <li><a href="http://www.ploscompbiol.org">PLOS Computational Biology</a></li>
          <li><a href="http://currents.plos.org">PLOS Currents</a></li>
          <li><a href="http://www.plosgenetics.org">PLOS Genetics</a></li>
          <li><a href="http://www.plospathogens.org">PLOS Pathogens</a></li>
          <li><a href="http://www.plosone.org">PLOS ONE</a></li>
          <li><a href="http://www.plosntds.org">PLOS Neglected Tropical Diseases</a></li>
        </ul>
      </div>
    </div>
    <div class="col col-3">
      <div class="nav">
        <p><a href="http://www.plos.org">plos.org</a></p>
        <p><a href="http://blogs.plos.org">Blogs</a></p>
        <p><a href="http://www.ploscollections.org">Collections</a></p>
        <p><a href="/feedback/new">Send us feedback</a></p>

        <p>California (US) corporation #C2354500, based in San Francisco</p>
      </div>
    </div>
  </div>
</div><!-- pageftr -->

</div><!-- end page-wrap, this div is in header.ftl -->
<script type="text/javascript" src="/javascript/jquery-1.8.1-min.js?v=Tm7VCOzZz3lE03ghpkS6SWkHbyI"></script>
<script type="text/javascript" src="/javascript/ga-min.js?v=lNQ4gt8QcPDatjsdOFl_FGpPhLY"></script>
<script type="text/javascript" src="/javascript/jquery.hoverIntent-min.js?v=mRiGNYY9cIXxVb8u0K_MdW7hHnc"></script>
<script type="text/javascript" src="/javascript/jquery.placeholder-min.js?v=21Pn56Ur9h1N4K4VZDa0nqI3Pxo"></script>
<script type="text/javascript" src="/javascript/jquery.jsonp-2.4.0-min.js?v=lqTpzoHfSq3I5Ygo01qq5WankEo"></script>
<script type="text/javascript" src="/javascript/jquery-ui-1.9.2.custom-min.js?v=raSSlfNO0YsV5uUpAKmTB9n5VTc"></script>
<script type="text/javascript" src="/javascript/jquery.tooltip-min.js?v=cw+6Smh+mdryIA25xvqIvHMrnZM"></script>
<script type="text/javascript" src="/javascript/jquery.uniform-min.js?v=kYUAnX6W2W_2fK3RIuQ2m_YFG9U"></script>
<script type="text/javascript" src="/javascript/jquery.pjax-min.js?v=939kLBjL5_YKbx71T1RHjYaD4l8"></script>
<script type="text/javascript" src="/javascript/imagesloaded-min.js?v=XeuAp8Gc3mvQUo+wZCSF8ttPwvw"></script>
<script type="text/javascript" src="/javascript/figviewer-min.js?v=yPUa0sUQ_iHkI+IRv2i9bjyZJFo"></script>
<script type="text/javascript" src="/javascript/global-min.js?v=0Q3PwjeaWtXYDnqIsQvnL_ou0qs"></script>
<script type="text/javascript" src="/javascript/jquery.touchswipe-min.js?v=huaek_e6HqTduvCNAN91dJolTyw"></script>
<script type="text/javascript" src="/javascript/jquery.base64-min.js?v=VwV1zeVqKZj5FCAdlK0q5NRxbBg"></script>
<script type="text/javascript" src="/javascript/alm-min.js?v=Y5gm6B0b4Kx2YHNObNrgEeBgXlY"></script>
<script type="text/javascript" src="/javascript/taxonomy-browser-min.js?v=vBVMuDMYkGJCXIUxLe35GoyiJNw"></script>
<script type="text/javascript" src="/javascript/jquery.filterize-min.js?v=j0ZKVnHyk2nhFy8eIuNJkp7xaM0"></script>
<script type="text/javascript" src="/javascript/plosone-min.js?v=TK4H4arL_XBSwwJq+K1N3kqYfAI"></script>
<script type="text/javascript" src="/javascript/twitter-min.js?v=xKgcxLsQFXy+at1ao1NVke8nFlM"></script>
<script type="text/javascript" src="/javascript/crossmark.1.4-min.js?v=3FO4k0SjwTaGNnKGNSqthar1080"></script>
<script type="text/javascript">
  var _sf_async_config={uid:16579,domain:"plosone.org"};
  (function(){
    function loadChartbeat() {
      window._sf_endpt=(new Date()).getTime();
      var e = document.createElement('script');
      e.setAttribute('language', 'javascript');
      e.setAttribute('type', 'text/javascript');
      e.setAttribute('src',
          (("https:" == document.location.protocol) ? "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" : "http://static.chartbeat.com/") +
              "js/chartbeat.js");
      document.body.appendChild(e);
    }
    var oldonload = window.onload;
    window.onload = (typeof window.onload != 'function') ?
        loadChartbeat : function() { oldonload(); loadChartbeat(); };
  })();
</script>
<!-- <script type="application/javascript" src="http://crossmark.crossref.org/javascripts/v1.3/crossmark.min.js"></script> -->

</body>
</html>
